Antiviral prodrugs and uses thereof

By developing compound (I) as a prodrug of emtricitabine or lamivudine, the problems of low phosphorylation efficiency of nucleoside analogs and toxicity of aminophosphate prodrugs have been solved, achieving highly effective antiviral treatment for HIV and HBV.

CN118908998APending Publication Date: 2024-11-08SHANGHAI CUREGENE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410956191.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-02-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing nucleoside analog prodrugs have low efficiency during phosphorylation, which limits their effectiveness as viral replication inhibitors. Furthermore, aminophosphate prodrugs pose risks of neurotoxicity and liver and kidney damage.

Method used

A novel compound has been developed, having a compound of formula (I) or a pharmaceutically acceptable salt thereof, as a prodrug of emtricitabine or lamivudine, which can be converted in vivo into the active triphosphate form, thereby improving the stability and efficacy of nucleoside analogs and reducing toxicity.

Benefits of technology

It improved the activity and pharmacokinetic properties of nucleoside analogs in vivo, enhanced their antiviral activity against HIV and HBV, and reduced the risk of toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908998A_ABST
    Figure CN118908998A_ABST
Patent Text Reader

Abstract

The present application relates to a compound of formula (I): # imgabs0 # or a pharmaceutically acceptable salt thereof. These compounds are useful as prodrugs of emtricitabine (FTC) or lamivudine (3TC) for inhibiting viral infections, such as human hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection. In addition, the present application also relates to pharmaceutical compositions comprising these compounds, and the use of these compounds or pharmaceutical compositions for the prevention and treatment of viral infections in subjects in need thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application with application number 202410155154.1, application date February 2, 2024, and invention name “Antiviral prodrugs and their uses”. Technical Field

[0002] The present disclosure relates to compounds used as prodrugs of entricitabine (FTC) or lamivudine (3TC) or pharmaceutically acceptable salts thereof, pharmaceutical compositions and preparations containing the same, and their use in treating viral infections, particularly infections caused by hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Background Art

[0003] Nucleoside analogs and their prodrug derivatives have been used to treat and prevent human immunodeficiency virus (HIV) infection and hepatitis B virus (HBV). Emtricitabine and lamivudine, as synthetic nucleoside analogs, have activity against both HIV and HBV, and emtricitabine is very similar to lamivudine in terms of activity, safety and resistance characteristics; the difference between the two is that the former has a longer half-life in the human body and is suitable for once-a-day administration by oral administration.

[0004] However, nucleoside analogs require host or viral kinase-mediated conversion to their therapeutically active triphosphate forms before being incorporated into elongated DNA or RNA, thereby causing chain termination. Therefore, the efficiency of nucleosides converted into active triphosphates and the concentration of triphosphates and the half-life in cells are very important factors determining the efficiency of nucleoside analogs as viral replication inhibitors. The first step of phosphorylation is crucial for preparing active triphosphates. When nucleosides themselves are not good substrates for kinases in the first step of phosphorylation, it is necessary to deliver nucleoside monophosphates.

[0005] Therefore, many efforts have been made to develop nucleotide prodrug strategies.For example, it has been found that phosphoramidate ProTide technology can improve the in vitro and in vivo activity and pharmacokinetics of the nucleoside analogs comprising thymine, uracil and adenine.However, this prodrug technology cannot improve the effectiveness of the nucleoside analogs consisting of cytosine (see, for example, Antimicrobial Agents and Chemotherapy, January 2000, 173-177 pages).In addition, the phosphoramidate strategy has various restrictions (Carcinogenesis 1993,14,2477 due to the potential neurotoxicity and liver and kidney damage caused by the phenol released by prodrug; Mutat.Res.1991,249,201).

[0006] There remains a need to further develop new prodrugs of nucleoside analogs with further improved stability, efficacy and toxicity. Summary of the invention

[0007] In one aspect, the present disclosure relates to compounds having formula (I):

[0008]

[0009] or a pharmaceutically acceptable salt thereof, wherein:

[0010] X is hydrogen or halogen;

[0011] R 1 is selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more Ra;

[0012] R a is selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy or alkynyloxy;

[0013] R 2 and R 3 are each independently hydrogen or optionally substituted by one or more R b substituted alkyl; or

[0014] R 2 and R 3 Together with the carbon to which they are both attached, they form a cycloalkyl or heterocyclyl group, wherein the cycloalkyl and heterocyclyl groups are optionally substituted by one or more R c replace;

[0015] R b and R c are each independently selected from halogen, cyano, hydroxy, amino, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol or arylthiol, wherein the alkyl, alkenyl, alkynyl, aryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol and arylthiol are optionally substituted by one or more R d replace;

[0016] R d is selected from halogen, cyano, hydroxy, amino, alkyl or alkoxy;

[0017] L is -N(R 4 )(R 5 );

[0018] R 4 and R5 are each independently hydrogen or optionally substituted by one or more R e Substituted alkyl;

[0019] or R 4 and R 5 Together with the nitrogen to which they are both attached, they form a f substituted heterocyclyl; and

[0020] R e and R f are each independently selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol or arylthiol, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol and arylthiol are optionally replaced by one or more R d replace.

[0021] In some embodiments, provided are compounds having Formula (Ia), (Ib) or (Ic):

[0022]

[0023] or a pharmaceutically acceptable salt thereof.

[0024] In another aspect, the present disclosure relates to pharmaceutical compositions comprising one or more compounds of the present disclosure, or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients.

[0025] In yet another aspect, the present disclosure relates to a pharmaceutical composition comprising one or more compounds of the present disclosure or a pharmaceutically acceptable salt thereof, and one or more other agents selected from antiviral agents, immunotherapeutic agents, or anti-infective agents.

[0026] In yet another aspect, the present disclosure relates to formulations comprising one or more compounds of the present disclosure or pharmaceutically acceptable salts thereof.

[0027] In yet another aspect, the present disclosure relates to a method for preventing or treating a viral infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure.

[0028] In another aspect, the present disclosure relates to use of a compound of the present disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the present disclosure in the preparation of a medicament for preventing or treating a viral infection in a subject. DETAILED DESCRIPTION

[0029] Please refer to certain embodiments of the present invention for details, examples of which are illustrated in the accompanying structures and formulas. Although the present invention will be described in conjunction with the enumerated embodiments, it should be understood that it is not intended that the present invention will be limited to those embodiments. On the contrary, the present invention is intended to cover all alternatives, modifications or equivalents, which may be included within the scope of the present invention as defined in the claims. Those skilled in the art will recognize many methods or materials that can implement the present invention that are similar or equivalent to those methods or materials described herein. The present invention is in no way limited to the methods or materials described. In the event that one or more of the incorporated references and similar materials (including but not limited to defined terms, term usage, described techniques, etc.) are different from or contradictory to the present application, the present invention shall prevail. All references, patents, and patent applications cited in the present invention are incorporated herein by reference in their entirety.

[0030] It should be appreciated that certain features of the invention described in the context of different embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the invention described in the context of a single embodiment for brevity may also be provided separately or in any suitable sub-combination.

[0031] It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an" and "the" include plural forms thereof unless the context clearly dictates otherwise. Thus, for example, reference to a "compound" includes a plurality of compounds. In this specification and the claims that follow, reference will be made to certain terms, which shall be defined as having the following meanings, unless there is an obvious contrary intention.

[0032] definition

[0033] Definitions of specific functional groups and chemical terms are described in more detail below.For purposes of the present invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th ed., inside cover, and specific functional groups are generally defined as described therein. In addition, general principles of organic chemistry as well as specific functional groups and reactivity are described in Organic Chemistry, Thomas Sorrell, 2nd edition, University Science Books, Sausalito, 2006; Smith and March, March's Advanced Organic Chemistry, 6th edition, John Wiley & Sons, Inc., New York, 2007; Larock, Comprehensive Organic Transformations, 3rd edition, VCH Publishers, Inc., New York, 2018; Carruthers, Some Modern Methods of Organic Synthesis, 4th edition, Cambridge University Press, Cambridge, 2004; the entire contents of each of which are incorporated herein by reference.

[0034] In various places of the present invention, linking substituents are described. Where a structure clearly requires a linking group, the Markush variable listed for that group is to be understood as a linking group. For example, if a structure requires a linking group and the Markush group definition for that variable lists "alkyl", it is to be understood that the "alkyl" means a linking alkylene group.

[0035] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then the substituent may be bonded to any atom on the ring. When a substituent is listed without indicating that the substituent is bonded to an atom in the remainder of a compound of a given formula, then the substituent may be bonded via any atom in the formula. Combinations of substituents and / or variables are permissible, but only if the combinations result in stable compounds.

[0036] When any variable (such as R i) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown as having 0-2 R i If the group is partially substituted, then the group may be optionally substituted with up to two R i Partially substituted, and R i In each occurrence, independently selected from i Also, combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0037] As used herein, the term “C i-j " indicates a range of carbon atoms, wherein i and j are integers, and the range of carbon atoms includes the endpoints (i.e., i and j) and every integer point therebetween, and wherein j is greater than i. For example, C 1-6 Indicates a range of one to six carbon atoms, including one carbon atom, two carbon atoms, three carbon atoms, four carbon atoms, five carbon atoms, and six carbon atoms. In some embodiments, the term "C 1-12 ” indicates 1 to 12, especially 1 to 10, especially 1 to 8, especially 1 to 6, especially 1 to 5, especially 1 to 4, especially 1 to 3 or especially 1 to 2 carbon atoms.

[0038] As used herein, the term "alkyl", whether used as part of another term or independently, refers to a saturated straight or branched chain hydrocarbon group, which may be optionally substituted independently with one or more substituents as described below. i-j "Alkyl" refers to an alkyl group having i to j carbon atoms. In some embodiments, the alkyl group contains 1 to 10 carbon atoms, 1 to 9 carbon atoms, 1 to 8 carbon atoms, 1 to 7 carbon atoms, 1 to 6 carbon atoms, 1 to 5 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. "C 1-10 Examples of “alkyl” include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, and the like.

[0039] As used herein, the term "alkenyl", whether used as part of another term or independently, refers to a straight or branched hydrocarbon group having at least one carbon-carbon double bond, which may be optionally substituted independently with one or more substituents as described herein, and includes groups having "cis" and "trans" configurations, or alternatively, "E" and "Z" configurations. In some embodiments, the alkenyl group contains 2 to 12 carbon atoms. In some embodiments, the alkenyl group contains 2 to 11 carbon atoms. In some embodiments, the alkenyl group contains 2 to 11 carbon atoms, 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkenyl group contains 2 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl (allyl), butenyl, pentenyl, 1-methyl-2-but-1-enyl, 5-hexenyl, and the like.

[0040] As used herein, the term "alkynyl" refers to a straight or branched hydrocarbon group having at least one carbon-carbon triple bond, whether used as part of another term or independently, which may be optionally substituted independently with one or more substituents described herein. In some embodiments, the alkynyl group contains 2 to 12 carbon atoms. In some embodiments, the alkynyl group contains 2 to 11 carbon atoms. In some embodiments, the alkynyl group contains 2 to 11 carbon atoms, 2 to 10 carbon atoms, 2 to 9 carbon atoms, 2 to 8 carbon atoms, 2 to 7 carbon atoms, 2 to 6 carbon atoms, 2 to 5 carbon atoms, 2 to 4 carbon atoms, 2 to 3 carbon atoms, and in some embodiments, the alkynyl group contains 2 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, and the like.

[0041] As used herein, the term "alkoxy", whether used as part of another term or by itself, refers to an alkyl group as previously defined, attached to the parent molecular moiety through an oxygen atom. i-j "Alkoxy" means that the alkyl portion of the alkoxy group has i to j carbon atoms. For example, the alkoxy group contains 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 carbon atoms. "C 1-6 Examples of "alkoxy" include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), tert-butoxy, neopentoxy, n-hexoxy, and the like.

[0042] As used herein, the term "alkenyloxy," whether used as part of another term or by itself, refers to an alkenyl group as previously defined, attached to the parent molecular moiety through an oxygen atom. i-j"Alkenyloxy" means that the alkenyl portion of the alkenyloxy group has i to j carbon atoms. For example, the alkenyloxy group contains 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3 carbon atoms. "C 2-6 Examples of "alkenyloxy" include, but are not limited to, vinyloxy, propenyloxy, butenyloxy, pentenyloxy, hexenyloxy, and the like.

[0043] As used herein, the term "alkynyloxy," whether used as part of another term or by itself, refers to an alkynyl group as previously defined, attached to the parent molecular moiety through an oxygen atom. i-j "Alkynyloxy" means that the alkynyl portion of the alkynyloxy group has i to j carbon atoms. For example, the alkynyloxy group contains 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3 carbon atoms. "C 2-6 Examples of "alkynyloxy" include, but are not limited to, ethynyloxy, propynyloxy, butynyloxy, pentynyloxy, hexynyloxy, and the like.

[0044] As used herein, the term "alkylthiol", whether used as part of another term or by itself, refers to an alkyl group as previously defined, attached to the parent molecule through a sulfur atom. i-j "Alkylthiol" means that the alkyl portion of the alkylthiol group has i to j carbon atoms. For example, the alkylthiol group contains 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 carbon atoms. "C 1-6 Examples of "alkyl mercaptan" include, but are not limited to, methyl mercaptan, ethyl mercaptan, propyl mercaptan (e.g., n-propyl mercaptan and isopropyl mercaptan), tert-butyl mercaptan, neopentyl mercaptan, n-hexyl mercaptan, and the like.

[0045] As used herein, the term "alkenyl thiol", whether used as part of another term or by itself, refers to an alkenyl group as previously defined, attached to the parent molecule through a sulfur atom. i-j “Alkenylthiol” means that the alkenyl portion of the alkenylthiol group has i to j carbon atoms. For example, the alkenylthiol group contains 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3 carbon atoms. “C 2-6 Examples of "alkenyl mercaptan" include, but are not limited to, ethylene mercaptan, propylene mercaptan, butylene mercaptan, pentene mercaptan, hexene mercaptan, and the like.

[0046] As used herein, the term "alkynyl thiol" whether used as part of another term or by itself, refers to an alkynyl group as previously defined, attached to the parent molecular moiety through a sulfur atom. i-j"Alkynylthiol" means that the alkynyl portion of the alkynylthiol group has i to j carbon atoms. For example, the alkynylthiol group contains 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3 carbon atoms. "C 2-6 Examples of "alkynyl mercaptan" include, but are not limited to, acetylene mercaptan, propynyl mercaptan, butynyl mercaptan, pentynyl mercaptan, hexynyl mercaptan, and the like.

[0047] As used herein, the term "amino" refers to a -NH2 group. The amino group may also be substituted with one or more groups such as alkyl, aryl, carbonyl or other amino groups.

[0048] Whether used as part of another term or independently, as used herein, the term "aryl" refers to monocyclic and polycyclic (including but not limited to bicyclic, tricyclic or tetracyclic) hydrocarbon ring systems having a total of 6 to 30 ring members, wherein at least one ring in the system is aromatic. In the case of a polycyclic system, it may include a fused ring or a spiro ring system. For example, a polycyclic aryl may include an aromatic ring fused to one or more additional rings (e.g., a cycloalkyl or aromatic ring). In some embodiments, aryl is C6-C 12 In some embodiments, aryl is C6-C 11 In some embodiments, aryl is C6-C 10 Aryl. In some embodiments, the aryl group is a C6-C9 aryl group. In some embodiments, the aryl group is a C6-C8 aryl group. Examples of aryl groups include, but are not limited to, aryl groups derived from hydrocarbon ring systems of anthracene, naphthylene, phenanthrene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indene, s-indene, indane, indene, naphthalene, phenanthren, phenanthren, pyrene, pyrene, and triphenylene. Unless otherwise specifically stated in the specification, the aryl group is optionally substituted at one or more ring positions with a substituent as described herein.

[0049] As used herein, the term "aryloxy," whether used as part of another term or by itself, refers to an aryl group, as previously defined, attached to the parent molecular moiety through an oxygen atom.

[0050] As used herein, the term "arylthiol," whether used as part of another term or by itself, refers to an aryl group, as previously defined, attached to the parent molecule through a sulfur atom.

[0051] Whether used as part of another term or independently, as used herein, the term "cycloalkyl" refers to non-aromatic, saturated or partially unsaturated monocyclic and polycyclic ring systems, wherein all ring atoms are carbon, and the ring system contains at least three ring-forming carbon atoms. In some embodiments, the cycloalkyl may contain 3 to 12 ring-forming carbon atoms, 3 to 10 ring-forming carbon atoms, 3 to 9 ring-forming carbon atoms, 3 to 8 ring-forming carbon atoms, 3 to 7 ring-forming carbon atoms, 3 to 6 ring-forming carbon atoms, 3 to 5 ring-forming carbon atoms, 4 to 12 ring-forming carbon atoms, 4 to 10 ring-forming carbon atoms, 4 to 9 ring-forming carbon atoms, 4 to 8 ring-forming carbon atoms, 4 to 7 ring-forming carbon atoms, 4 to 6 ring-forming carbon atoms, 4 to 5 ring-forming carbon atoms. Cycloalkyl may be saturated or partially unsaturated. In some embodiments, the cycloalkyl may be a saturated cyclic alkyl. In some embodiments, the cycloalkyl may be a partially unsaturated cyclic alkyl containing at least one double bond or triple bond in its ring system. Unless stated otherwise specifically in the specification, a cycloalkyl group is optionally substituted at one or more ring positions with substituents as described herein.

[0052] In some embodiments, the cycloalkyl group can be a saturated or partially unsaturated monocyclic carbocyclic ring system, examples of which include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, and cyclododecyl.

[0053] In some embodiments, the cycloalkyl group can be a saturated or partially unsaturated polycyclic (e.g., bicyclic and tricyclic) carbocyclic ring system, which can be arranged into a condensed ring system, a spirocyclic ring system, or a bridged ring system. As used herein, the term "condensed ring" refers to a ring system having two rings sharing two adjacent atoms, the term "spirocyclic ring" refers to a ring system having two rings connected by a single common atom, and the term "bridged ring" refers to a ring system having two rings sharing three or more atoms. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptane. 。

[0054] As used herein, the term "cyano" refers to -CN.

[0055] As used herein, the term "halo" or "halogen" refers to an atom selected from fluorine (or fluoro), chlorine (or chloro), bromine (or bromo) and iodine (or iodo).

[0056] As used herein, the term "haloalkyl" refers to an alkyl group substituted with one or more halogen atoms.

[0057] As used herein, the term "haloalkoxy" refers to an alkoxy group substituted with one or more halogen atoms.

[0058] As used herein, the term "haloaryl" refers to an aryl group substituted with one or more halogen atoms.

[0059] As used herein, the term "heteroalkyl" refers to an alkyl group in which at least one of the carbon atoms is replaced by a heteroatom selected from N, O or S. The heteroalkyl group may be a carbon radical or a heteroatom radical (i.e., a heteroatom may appear in the middle or at the end of the radical), and may be optionally substituted independently by one or more substituents described herein. The term "heteroalkyl" includes alkoxy radicals and heteroalkoxy radicals.

[0060] As used herein, the term "heteroalkenyl" refers to an alkenyl group in which at least one of its carbon atoms is replaced by a heteroatom selected from N, O or S. The heteroalkenyl group may be carbonyl or heteroatomyl (i.e., the heteroatom may appear in the middle or at the terminal end of the group), and may be optionally substituted independently with one or more substituents described herein.

[0061] As used herein, the term "heteroalkynyl" refers to an alkynyl group in which at least one of its carbon atoms is replaced by a heteroatom selected from N, O or S. A heteroalkynyl group may be a carbon group or a heteroatom group (i.e., the heteroatom may appear in the middle or at a terminal end of the group), and may be optionally substituted independently with one or more substituents described herein.

[0062] As used herein, the term "heteroaryl", whether used as part of another term or independently, refers to an aryl group having one or more heteroatoms that can be optionally oxidized or quaternized in addition to carbon atoms. Heteroaryl can be a monocyclic or polycyclic (e.g., bicyclic, tricyclic or tetracyclic) ring system. In the case of a polycyclic system, it can include a fused ring or a spiro ring system. For example, a polycyclic heteroaryl may include a heteroaryl ring fused to one or more additional rings (e.g., cycloalkyl, heterocyclyl, aryl or heteroaryl ring), or an aryl ring fused to one or more additional rings (e.g., heterocyclyl or heteroaryl ring). In some embodiments, heteroaryl is a 5 to 12-membered heteroaryl. In some embodiments, heteroaryl is a 5 to 10-membered heteroaryl. In some embodiments, heteroaryl is a 5 to 6-membered heteroaryl. In some embodiments, heteroaryl is a 6-membered heteroaryl. In some embodiments, heteroaryl is a 5-membered heteroaryl. Examples of heteroaryl groups include, but are not limited to, acridinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxaheptyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranyl, benzofuranyl, benzofuranyl, benzothiophenyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnamyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furanyl, isothiazolyl, imidazole 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyridyl, pyridyl 1-oxide, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidine, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thienyl. In some embodiments, the term "5- to 10-membered heteroaryl" refers to a 5- to 6-membered heteroaryl ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8- to 10-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, the term "5- to 12-membered heteroaryl" refers to a 5- to 6-membered heteroaryl ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8- to 12-membered bicyclic heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Unless otherwise specifically stated in the specification, the heteroaryl group may be optionally substituted at one or more ring positions by a substituent as described herein.

[0063] As used herein, the term "heteroatom" refers to nitrogen, oxygen, sulfur, or phosphorus, and includes any oxidized form of the nitrogen or sulfur, and any quaternized form of a basic nitrogen.

[0064] As used herein, the term "heterocyclic group", whether used as part of another term or independently, refers to a partially or fully saturated 3 to 24-membered ring group containing 2 to 23 carbon atoms and 1 to 8 heteroatoms, the heteroatoms being selected from the group consisting of nitrogen, oxygen, phosphorus, silicon and sulfur, which may be optionally oxidized or quaternized. In some embodiments, the heterocyclic group is fully saturated. In some embodiments, the heterocyclic group is partially unsaturated. The heterocyclic group may be a monocyclic or polycyclic (e.g., bicyclic, tricyclic or tetracyclic) ring system. In the case of a polycyclic system, it may include a fused ring, a spirocyclic or a bridged ring system. For example, a polycyclic heterocyclic group may include a heterocyclic group fused to one or more other rings (e.g., cycloalkyl or heterocyclic group), or a cycloalkyl group fused to one or more heterocyclic groups. Examples of heterocyclic groups include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, dihydrofuranyl, thienyl[1,3]dithienyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, Pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3-dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxane-4-yl and 2-oxo-1,3-dioxane-4-yl. In some embodiments, the heterocyclyl is a 3- to 12-membered heterocyclyl. In some embodiments, the heterocyclyl is a 3- to 9-membered heterocyclyl. In some embodiments, the heterocyclyl is a 3- to 8-membered heterocyclyl. In some embodiments, the heterocyclyl is a 3- to 7-membered heterocyclyl. In some embodiments, the heterocyclyl is a 3- to 6-membered heterocyclyl. In some embodiments, the heterocyclyl is a 4- to 6-membered heterocyclyl. In some embodiments, the heterocyclyl is a 5- to 6-membered heterocyclyl.Unless stated otherwise specifically in the specification, the heterocyclyl may be optionally substituted at one or more ring positions with substituents as described herein.

[0065] As used herein, the term "hydroxy" refers to -OH.

[0066] As used herein, the term "nitro" refers to -NO2.

[0067] As used herein, the term "partially unsaturated" refers to a group that includes at least one double or triple bond. The term "partially unsaturated" is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic (ie, fully unsaturated) moieties.

[0068] As used herein, the term "substituted", whether or not there is the term "optionally" in front, means that one or more hydrogens of the specified part are replaced by suitable substituents. It should be understood that "replacement" or "substituted" includes the following implicit restrictions: the substitution is consistent with the allowed valence of the substituted atom, and the substitution produces a stable or chemically feasible compound, such as a compound that will not spontaneously transform by rearrangement, cyclization, elimination, etc. Unless otherwise specified, the "optionally substituted" group can have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted by more than one substituent selected from a specified group, the substituent can be the same or different at each position. It should be understood by those skilled in the art that the substituent itself can be substituted when appropriate. Unless specifically stated as "unsubstituted", reference to the chemical part herein should be understood to include substituted variants. For example, reference to "aryl" or "aryl" moieties implicitly includes both substituted and unsubstituted variants.

[0069] Compound

[0070] In one aspect, a compound having formula (I) is provided:

[0071]

[0072] or a pharmaceutically acceptable salt thereof, wherein:

[0073] X is hydrogen or halogen;

[0074] R 1 is selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are optionally substituted by one or more R a replace;

[0075] R a is selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy or alkynyloxy;

[0076] R 2 and R 3 are each independently hydrogen or optionally substituted by one or more R b substituted alkyl; or

[0077] R2 and R 3 Together with the carbon to which they are both attached, they form a cycloalkyl or heterocyclyl group, wherein the cycloalkyl and heterocyclyl groups are optionally substituted by one or more R c replace;

[0078] R b and R c are each independently selected from halogen, cyano, hydroxy, amino, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol or arylthiol, wherein the alkyl, alkenyl, alkynyl, aryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol and arylthiol are optionally substituted by one or more R d replace;

[0079] R d is selected from halogen, cyano, hydroxy, amino, alkyl or alkoxy;

[0080] L is -N(R 4 )(R 5 );

[0081] R 4 and R 5 are each independently hydrogen or optionally substituted by one or more R e Substituted alkyl;

[0082] or R 4 and R 5 Together with the nitrogen to which they are both attached, they form a f substituted heterocyclyl; and

[0083] R e and R f are each independently selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol or arylthiol, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylthiol, alkenylthiol, alkynylthiol and arylthiol are optionally replaced by one or more R d replace.

[0084] In some embodiments, X is hydrogen.

[0085] In some embodiments, X is halogen. In certain embodiments, X is fluorine.

[0086] In some embodiments, R 1 is optionally represented by one or more R aIn some embodiments, R 1 is optionally represented by one or more R a Substituted C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 In some embodiments, each R a Independently selected from halogen, cyano, hydroxy, amino, alkyl or alkoxy.

[0087] In certain embodiments, R 1 It is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or 2-ethylbutyl.

[0088] In some embodiments, R 1 is optionally represented by one or more R a In some embodiments, R 1 is optionally represented by one or more R a Substituted C 2-6 Alkenyl, C 2-5 Alkenyl, C 2-4 Alkenyl or C 2-3 In some embodiments, each R a Independently selected from halogen, hydroxy, cyano, amino, alkyl or alkoxy.

[0089] In certain embodiments, R 1 It is vinyl, propenyl or butenyl.

[0090] In some embodiments, R 1 is optionally represented by one or more R a In some embodiments, R 1 is optionally represented by one or more R a Substituted C 2-6 Alkynyl, C 2-5 Alkynyl, C 2-4 Alkynyl or C 2-3 In some embodiments, each R a Independently selected from halogen, hydroxy, cyano, amino, alkyl or alkoxy.

[0091] In certain embodiments, R 1 is ethynyl, 1-propynyl or 2-propynyl.

[0092] In some embodiments, R 1 is optionally represented by one or more R a In some embodiments, R 1 is optionally represented by one or more R aSubstituted C 3-7 Cycloalkyl, C 3-6 Cycloalkyl, C 3-5 Cycloalkyl or C 3-4 In some embodiments, each R a Independently selected from halogen, hydroxy, cyano, amino, alkyl or alkoxy.

[0093] In certain embodiments, R 1 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0094] In some embodiments, R 2 and R 3 One of them is hydrogen, and the other is optionally substituted by one or more R b In some embodiments, R 2 and R 3 One of them is hydrogen, and the other is optionally substituted by one or more R b Substituted C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 In some embodiments, each R b Independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy or phenyl.

[0095] In certain embodiments, R 2 and R 3 One of them is hydrogen, and the other is methyl, ethyl, n-propyl or isopropyl.

[0096] In certain embodiments, R 2 and R 3 One of them is hydrogen and the other is methyl.

[0097] In certain embodiments, R 2 and R 3 One of them is hydrogen and the other is ethyl.

[0098] In some embodiments, R 2 and R 3 are each independently optionally replaced by one or more R b In some embodiments, R 2 and R 3 Each independently is optionally replaced by one or more R b Substituted C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 In some embodiments, each Rb Independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy or phenyl.

[0099] In certain embodiments, R 2 and R 3 Each is independently methyl, ethyl or n-propyl.

[0100] In certain embodiments, R 2 and R 3 Both are methyl groups.

[0101] In some embodiments, R 2 and R 3 Together with the carbon to which they are both attached, they form a c In certain embodiments, R 2 and R 3 Together with the carbon to which they are both attached, they form a c Substituted C 3-7 Cycloalkyl, C 3-6 Cycloalkyl, C 3-5 Cycloalkyl or C 3-4 In some embodiments, each R c Independently selected from halogen, hydroxy, cyano, amino, alkyl or alkoxy.

[0102] In certain embodiments, R 2 and R 3 Together with the carbon to which they are both attached they form a cyclopropyl or cyclobutyl group.

[0103] In some embodiments, R 2 and R 3 Together with the carbon to which they are both attached, they form a c In certain embodiments, R 2 and R 3 Together with the carbon to which they are both attached, they form a c substituted 3 to 7 membered heterocyclyl, 3 to 6 membered heterocyclyl, 3 to 5 membered heterocyclyl, or 3 to 4 membered heterocyclyl. c Independently selected from halogen, hydroxy, cyano, amino, alkyl or alkoxy.

[0104] In some embodiments, R 1 is optionally represented by one or more R a substituted alkyl, and R 2 and R 3 are each independently hydrogen or optionally substituted by one or more R b Substituted alkyl.

[0105] In some embodiments, R 1 is optionally represented by one or more R a Substituted alkyl, R 2 and R 3 One of them is hydrogen, and the other is optionally substituted by one or more R b Substituted alkyl.

[0106] In certain embodiments, R 1 is optionally represented by one or more R a Substituted C 1-6 Alkyl, R 2 and R 3 One of them is hydrogen, and the other is optionally substituted by one or more R b Substituted C 1-6 Alkyl, where R a are independently selected from halogen, hydroxy, cyano, amino, alkyl or alkoxy, and R b Independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy or phenyl.

[0107] In certain embodiments, R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or 2-ethylbutyl, R 2 and R 3 One of them is hydrogen and the other is selected from methyl, ethyl, n-propyl or isopropyl.

[0108] In certain embodiments, R 1 is ethyl, isopropyl or n-butyl, R 2 and R 3 One of them is hydrogen, and the other is methyl or ethyl.

[0109] In some embodiments, R 1 is optionally represented by one or more R a substituted alkyl, and R 2 and R 3 Each independently is optionally replaced by one or more R b Substituted alkyl.

[0110] In certain embodiments, R 1 is optionally represented by one or more R a Substituted C 1-6 Alkyl, and R 2 and R 3 Each independently is optionally replaced by one or more R b Substituted C 1-6 Alkyl, where R aare independently selected from halogen, hydroxy, cyano, amino, alkyl or alkoxy, and R b Independently selected from halogen, hydroxy, cyano, amino, alkyl, alkoxy or phenyl.

[0111] In certain embodiments, R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl or 2-ethylbutyl, R 2 and R 3 Each is independently selected from methyl, ethyl, n-propyl or isopropyl.

[0112] In certain embodiments, R 1 is ethyl or isopropyl, R 2 and R 3 Both are methyl groups.

[0113] In some embodiments, L is -N(R 4 )(R 5 ).

[0114] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 One of them is hydrogen, and the other is optionally substituted by one or more R independently selected from halogen, hydroxy, cyano or alkoxy e Substituted alkyl.

[0115] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 One of them is hydrogen, and the other is optionally substituted by one or more R independently selected from halogen, hydroxy, cyano or alkoxy e Substituted C 1-6 alkyl.

[0116] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 One of them is hydrogen, and the other is methyl, ethyl, n-propyl or isopropyl.

[0117] In some embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Each independently represents an alkyl group, the alkyl group is optionally substituted by one or more R independently selected from halogen, cyano, amino, alkyl or alkoxy e replace.

[0118] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Each independently is optionally replaced by one or more R e Substituted C 1-6 Alkyl, where R e are independently halogen, cyano, amino, alkyl or alkoxy.

[0119] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Each is independently selected from methyl, ethyl, n-propyl, 2-methylpropyl, 2,2'-dimethylpropyl, n-butyl, 2-ethylbutyl, 3-methylbutyl, 3,3'-dimethylbutyl, n-pentyl, isopentyl, hexyl, heptyl or octyl.

[0120] In some embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form a f In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form a f In some embodiments, each R f independently selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl, aryl or aryloxy, wherein the alkyl, alkenyl, alkynyl, aryl and aryloxy are optionally substituted by one or more R independently selected from halogen, cyano or amino. d replace.

[0121] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form a f substituted heterocyclic group, the heterocyclic group is selected from piperidinyl, azetidinyl, piperazinyl, morpholinyl or 1,2,3,4-tetrahydro-isoquinolinyl. In some embodiments, each R findependently selected from halogen, hydroxy, cyano, amino, alkyl, alkenyl, alkynyl, aryl or aryloxy, wherein the alkyl, alkenyl, alkynyl, aryl and aryloxy are optionally substituted by one or more R independently selected from halogen, cyano or amino. d replace.

[0122] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form a f substituted heterocyclic group, the heterocyclic group is selected from piperidinyl, azetidinyl, piperazinyl, morpholinyl or 1,2,3,4-tetrahydro-isoquinolinyl. In some embodiments, each R f independently selected from aryl or aryloxy, wherein the aryl and aryloxy are optionally substituted by one or more R independently selected from halogen, cyano or amino d replace.

[0123] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they are optionally substituted with one or more R f substituted heterocyclic group, the heterocyclic group is selected from piperidinyl, azetidinyl, piperazinyl, morpholinyl or 1,2,3,4-tetrahydro-isoquinolinyl. In some embodiments, each R f Independently selected from C 5-12 Aryl or C 5-12 Aryloxy, wherein the C 5-12 Aryl or C 5-12 The aryloxy group is optionally substituted with one or more R independently selected from halogen, cyano or amino. d replace.

[0124] In certain embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form:

[0125]

[0126] In another aspect, a compound having formula (Ia) is provided:

[0127]

[0128] or a pharmaceutically acceptable salt thereof, wherein X, L and R 1As defined above.

[0129] In some embodiments, X is H.

[0130] In some embodiments, X is fluoro.

[0131] In some embodiments, R 1 C 1-6 alkyl.

[0132] In certain embodiments, R 1 It is ethyl or isopropyl.

[0133] In some embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Each is independently selected from methyl, ethyl, n-propyl, 2-methylpropyl or n-butyl.

[0134] In some embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form a 3- to 12-membered heterocyclic group, which is optionally substituted by one or more independently selected from C 1-6 Alkyl, C 3-7 Aryl, C 3-7 Aryl halide or C 3-7 R f replace.

[0135] In yet another aspect, a compound having formula (Ib) is provided:

[0136]

[0137] or a pharmaceutically acceptable salt thereof, wherein X, L and R 1 As defined above.

[0138] In some embodiments, X is H.

[0139] In some embodiments, X is fluoro.

[0140] In some embodiments, R 1 C 1-6 alkyl.

[0141] In certain embodiments, R 1 It is ethyl or n-butyl.

[0142] In some embodiments, L is -N(R 4 )(R 5), where R 4 and R 5 Each is independently selected from methyl, ethyl, n-propyl, 2-methylpropyl, 2-ethylbutyl, 3-methylbutyl or n-butyl.

[0143] In some embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form a 3- to 12-membered heterocyclic group, which is optionally substituted by one or more independently selected from C 1-6 Alkyl, C 3-7 Aryl or C 3-7 R f replace.

[0144] In yet another aspect, a compound having formula (Ic) is provided:

[0145]

[0146] or a pharmaceutically acceptable salt thereof, wherein X, L and R 1 As defined above.

[0147] In some embodiments, X is H.

[0148] In some embodiments, X is fluoro.

[0149] In some embodiments, R 1 C 1-6 alkyl.

[0150] In certain embodiments, R 1 It is ethyl or isopropyl.

[0151] In some embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Each is independently selected from methyl, ethyl, n-propyl, 2-methylpropyl, 2-ethylbutyl, 3-methylbutyl or n-butyl.

[0152] In some embodiments, L is -N(R 4 )(R 5 ), where R 4 and R 5 Together with the nitrogen to which they are both attached, they form a 3- to 12-membered heterocyclic group, which is optionally substituted by one or more independently selected from C 1-6 Alkyl, C 3-7 Aryl, C 3-7 Aryl halide or C 3-7R f replace.

[0153] In yet another aspect, the present invention provides a compound of formula (I) selected from:

[0154] 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(4-phenylpiperidin-1-yl)phosphoryl)amino)-2-methylpropanoic acid ethyl ester;

[0155] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(4-phenylpiperidin-1-yl)phosphoryl)amino)butyrate;

[0156] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(4-phenylpiperidin-1-yl)phosphoryl)amino)propanoate;

[0157] (2S)-butyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(4-phenylpiperidin-1-yl)phosphoryl)amino)propanoate;

[0158] 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(4-phenoxypiperidin-1-yl)phosphoryl)amino)-2-methylpropanoic acid ethyl ester;

[0159] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(4-phenoxypiperidin-1-yl)phosphoryl)amino)butyrate;

[0160] 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(dibutylamino)phosphoryl)amino)-2-methylpropanoic acid ethyl ester;

[0161] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(dibutylamino)phosphoryl)amino)butyrate;

[0162] 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(3,4-dihydroisoquinolin-2(1H)-yl)phosphoryl)amino)-2-methylpropanoic acid ethyl ester;

[0163] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(3,4-dihydroisoquinolin-2(1H)-yl)phosphoryl)amino)butyrate;

[0164] 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(diisopentylamino)phosphoryl)amino)-2-methylpropanoic acid ethyl ester;

[0165] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(diisopentylamino)phosphoryl)amino)butyrate;

[0166] (2S)-isopropyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(diisopentylamino)phosphoryl)amino)propanoate;

[0167] 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy

[0168] ethyl)(4-(2,4-difluorophenyl)piperidin-1-yl)phosphoryl)amino)-2-methylpropanoate;

[0169] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(4-(2,4-difluorophenyl)piperidin-1-yl)phosphoryl)amino)butyrate;

[0170] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(diisopentylamino)phosphoryl)amino)propanoate;

[0171] (2S)-butyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(diisopentylamino)phosphoryl)amino)propanoate;

[0172] (2S)-isopropyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(bis(2-ethylbutyl)amino)phosphoryl)amino)propanoate;

[0173] (2S)-ethyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(bis(2-ethylbutyl)amino)phosphoryl)amino)butyrate;

[0174] (2S)-butyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(bis(2-ethylbutyl)amino)phosphoryl)amino)propanoate; and

[0175] (2S)-isopropyl 2-(((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(bis(3,3-dimethylbutyl)amino)phosphoryl)amino)propanoate, or a pharmaceutically acceptable salt thereof.

[0176] Exemplary compounds of formula (I) provided by the present disclosure are listed in Table 1 below.

[0177] Table 1

[0178]

[0179]

[0180]

[0181]

[0182]

[0183] The compounds provided herein are described with reference to chemical formulae and specific compounds. In addition, the compounds of the invention may exist in many different forms or derivatives, all of which are within the scope of the invention. These include, for example, tautomers, stereoisomers, racemic mixtures, regioisomers, salts, solvated forms, amorphous forms, different crystalline forms or polymorphs.

[0184] Depending on the substituent selection, the compounds of the present invention may include one or more asymmetric centers, and therefore may exist in various stereoisomeric forms, such as enantiomers and / or diastereomers. For example, the compounds provided herein may have an asymmetric phosphorus center, and therefore the compounds of formula I provided herein may have (R) or (S) stereo configuration at the phosphorus asymmetric center. Therefore, the compounds of the present invention may be in the form of individual enantiomers, diastereomers or geometric isomers, or may be in the form of a mixture of stereoisomers.

[0185] As used herein, the term "enantiomer" refers to two stereoisomers of a compound that are non-superimposable mirror images of each other. The term "diastereomer" refers to a pair of optical isomers that are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties, and reactivity.

[0186] When a particular enantiomer is preferred, it may be provided in some embodiments as being substantially free of the relative enantiomer, and may also be referred to as "optically enriched". As used herein, "optically enriched" means that the compound is composed of a significantly larger proportion of one enantiomer. In certain embodiments, the compound is composed of at least about 90% by weight of the preferred enantiomer. In other embodiments, the compound is composed of at least about 95%, 98% by weight, or 99% by weight of the preferred enantiomer. The preferred enantiomer may be separated from the racemic mixture by any method known to those skilled in the art, such as by chromatography or crystallization, by synthesizing using stereochemically uniform starting materials, or by stereoselective synthesis. Optionally, derivatization may be performed before separating stereoisomers. The separation of a mixture of stereoisomers may be performed during the synthesis of the compounds provided herein at an intermediate step or it may be performed on the final racemic product. Absolute stereochemistry may be determined by X-ray crystallography of a crystalline product or a crystalline intermediate, which may be derivatized with a reagent containing a stereocenter of a known configuration if necessary. Alternatively, absolute stereochemistry can be determined by vibrational circular dichroism (VCD) spectroscopy. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, SH et al., Tetrahedron 33:2725 (1977); Eliel, EL Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, SH Tables of Resolving Agents and Optical Resolutions, p. 268 (ELEiel, ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

[0187] In some embodiments, a mixture of diastereomers is provided, for example, a mixture of diastereomers enriched with 51% or more of one of the diastereomers, including, for example, 60% or more, 70% or more, 80% or more, or 90% or more of one of the diastereomers.

[0188] In some embodiments, unless otherwise indicated, the compounds provided herein may have one or more double bonds that exist as Z or E isomers. Additionally, the present invention also encompasses compounds in the form of individual isomers that are substantially free of other isomers, and alternatively, in the form of mixtures of multiple isomers (e.g., racemic mixtures of enantiomers).

[0189] The compounds of the present invention can also exist in different tautomeric forms, and all such forms are encompassed within the scope of the present invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can be mutually converted via a low energy barrier. For example, proton tautomers (also referred to as prototransfer tautomers) include mutual conversions via proton migration, such as keto-enols, amide-imidic acids, lactams-lactams, imine-enamine isomerizations and cyclic forms, wherein protons can occupy two or more positions of heterocyclic systems (e.g., 1H-imidazoles and 3H-imidazoles, 1H-1,2,4-triazoles, 2H-1,2,4-triazoles and 4H-1,2,4-triazoles, 1H-isoindoles and 2H-isoindoles and 1H-pyrazoles and 2H-pyrazoles). Valence tautomers include mutual conversions by rearrangement of some bonding electrons. Tautomers can be in equilibrium or spatially locked into a form by appropriate substitution. Unless otherwise specified, a compound of the invention identified by name or structure as a particular tautomeric form is intended to encompass the other tautomeric forms.

[0190] The present invention is also intended to include all isotopes of atoms in the compounds. Isotopes of atoms include atoms having the same atomic number but different mass numbers. For example, unless otherwise specified, hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine or iodine in the compounds of the present invention are also intended to include their isotopes, such as (but not limited to) 1 H. 2 H. 3 H. 11 C. 12 C. 13 C. 14 C. 14 N. 15 N. 16 O. 17 O. 18 O. 31 P. 32 P. 32 S. 33 S. 34 S. 36 S. 17 F. 18 F. 19 F. 35 Cl, 37 Cl, 79Br, 81 Br, 124 I. 127 I and 131 1. In some embodiments, hydrogen comprises protium, deuterium, and tritium. In some embodiments, carbon comprises 12 C and 13 C. Isotopically enriched compounds of formula (I) may be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein, using appropriate isotopically enriched reagents and / or intermediates.

[0191] The compounds of the present invention may be formulated as or in the form of pharmaceutically acceptable salts. Unless specified to the contrary, the compounds provided herein include pharmaceutically acceptable salts of such compounds.

[0192] As used herein, the term "pharmaceutically acceptable" indicates that the substance or composition described is chemically and / or toxicologically compatible with the other ingredients making up the formulation and / or the individual being treated therewith.

[0193] As used herein, the term "subject" refers to an animal, preferably a mammal, and more preferably a human, that has been the object of treatment, observation or experiment.

[0194] As used herein, unless otherwise indicated, the term "pharmaceutically acceptable salt" includes salts that retain the biological effectiveness of the free acids and bases of the specified compound and are not biologically or otherwise undesirable. Pharmaceutically acceptable salt forms contemplated include, but are not limited to, monosalts, disalts, trisalts, tetrasalts, and the like. Pharmaceutically acceptable salts are nontoxic in the amounts and concentrations to which they are applied. The preparation of such salts can facilitate pharmacological use by changing the physical characteristics of the compound without preventing it from exerting its physiological effects. Useful changes in physical properties include lowering the melting point to facilitate transmucosal administration and increasing solubility to facilitate administration of higher concentrations of the drug.

[0195] Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, chloride, hydrochloride, fumarate, maleate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, maleic acid, sulfuric acid, phosphoric acid, sulfamate, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamate, fumaric acid and quinic acid.

[0196] When an acidic functional group (such as carboxylic acid or phenol) is present, pharmaceutically acceptable salts also include base addition salts, such as those containing the following: benzathine, chloroprocaine, choline, diethanolamine, ethanolamine, tert-butylamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, ammonium, alkylamines and zinc. See, for example, Remington's Pharmaceutical Sciences, 19th edition, Mack Publishing Co., Easton, PA, Vol. 2, p. 1457, 1995; Stahl and Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim, Germany, 2002. Such salts can be prepared using the appropriate corresponding bases.

[0197] Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free base form of the compound can be dissolved in a suitable solvent (such as an aqueous solution or water-alcohol solution containing a suitable acid), and then separated by evaporating the solution. Therefore, if the specific compound is a base, the desired pharmaceutically acceptable salt can be prepared by any suitable method available in the art, for example, with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. to treat the free base, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, pyranosyl acid (such as glucuronic acid or galacturonic acid), alpha-hydroxy acid (such as citric acid or tartaric acid), amino acid (such as aspartic acid or glutamic acid), aromatic acid (such as benzoic acid or cinnamic acid), sulfonic acid (such as p-toluenesulfonic acid or ethanesulfonic acid), etc. to treat the free base.

[0198] Similarly, if the particular compound is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, by treating the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or an alkaline earth metal hydroxide, etc. Illustrative examples of suitable salts include organic salts derived from amino acids (such as L-glycine, L-lysine and L-arginine), ammonia, primary, secondary and tertiary amines and cyclic amines, such as hydroxyethylpyrrolidine, piperidine, morpholine or piperazine; and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium.

[0199] It will also be understood that the compounds of the invention may exist in unsolvated forms, solvated forms (eg, hydrated forms), and solid forms (eg, anhydrates, crystals or polymorphs), and that the invention is intended to encompass all such forms.

[0200] As used herein, the term "solvate" or "solvated form" refers to a solvent addition form containing a stoichiometric or non-stoichiometric amount of a solvent. Some compounds have a tendency to entrap a fixed molar ratio of solvent molecules in a crystalline solid state, thereby forming a solvate. If the solvent is water, the solvate formed is a hydrate; and if the solvent is an alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with a molecule of a substance, wherein the water retains its molecular state as H2O. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.

[0201] As used herein, the terms "crystal form", "crystalline form", "polymorphic form" and "polymorph" are used interchangeably and refer to crystal structures in which a compound (or its salt or solvate) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms typically have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shapes, optical and electrical properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors can make one crystal form dominant. Crystalline polymorphs of a compound can be prepared by crystallization under different conditions.

[0202] The present invention is also intended to include all isotopes of atoms in the compounds. Isotopes of atoms include atoms having the same atomic number but different mass numbers. For example, unless otherwise specified, hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine or iodine in the compounds of the present invention are also intended to include their isotopes, such as (but not limited to) 1 H. 2 H. 3 H. 11 C. 12 C. 13 C. 14 C. 14 N. 15 N. 16 O. 17 O. 18 O. 31 P. 32 P. 32 S. 33 S. 34 S. 36 S. 17 F. 18 F.19 F. 35 Cl, 37 Cl, 79 Br, 81 Br, 124 I. 127 I and 131 1. In some embodiments, hydrogen comprises protium, deuterium, and tritium. In some embodiments, carbon comprises 12 C and 13 C.

[0203] The compounds disclosed herein are prodrugs. More specifically, the compounds of formula (I) provided herein or their pharmaceutically acceptable salts are prodrugs of emtricitabine or lamivudine. As used herein, the term "prodrug" refers to a compound or its pharmaceutically acceptable salt that produces a desired active compound when metabolized or converted by solvolysis under physiological conditions. Typically, a prodrug is inactive, or less active than an active compound, but may provide one or more favorable processing, administration and / or metabolic properties. A prodrug may be developed from a prodrug form to an active form in a single step, or may have one or more intermediate forms, which may themselves be active or may be inactive. The preparation and use of prodrugs are discussed in the following documents: T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems", Volume 14 of the ACSSymposium Series; "Bioreversible Carriers in Drug Design", edited by Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987; "Prodrugs: Challenges and Rewards", edited by V. Stella, R. Borchardt, M. Hageman, R. Oliyai, H. Maag, J. Tilley, Springer-Verlag New York, 2007; J. Rautio, FT Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, et al., "Prodrugs: design and clinical applications." Nat. Rev. Drug Discov. 2008, Volume 7, page 255, all of which are hereby incorporated by reference in their entirety.

[0204] Synthesis of compounds

[0205] The synthesis of the compound (including its pharmaceutically acceptable salt) provided herein is described in the synthesis scheme in the example. The compound provided herein can be prepared using any known organic synthesis technology and can be synthesized according to any of a variety of possible synthetic pathways, and therefore, these schemes are only illustrative and are not intended to limit other possible methods that can be used to prepare the compound provided herein. In addition, the steps in the scheme are to better illustrate and can be changed when appropriate. For the purpose of research and possible submission to the regulatory agency, the embodiment of the compound in the example is synthesized.

[0206] The reaction for preparing the compounds of the present invention can be carried out in a suitable solvent, which can be easily selected by a technician in the field of organic synthesis. Suitable solvents can be at a temperature at which the reaction is carried out, for example, at a temperature within the range of the freezing temperature of the solvent to the boiling temperature of the solvent, substantially not reacting with starting material (reactant), intermediate or product. The specified reaction can be carried out in a solvent or a mixture of more than one solvent. Depending on the specific reaction step, the suitable solvent for the specific reaction step can be selected by a technician in the field.

[0207] The reaction can be monitored by any suitable method known in the art. For example, the reaction can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g. 1 H or 13 C), infrared spectroscopy (IR), spectrophotometry (e.g., UV-visible light), mass spectrometry, or by chromatography, such as high performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LCMS) or thin layer chromatography (TLC) to monitor product formation. Those skilled in the art can purify compounds by a variety of methods, including high performance liquid chromatography (HPLC) ("Preparative LC-MS Purification: Improved Compound Specific Method Optimization", Karl F. Blom, Brian Glass, Richard Sparks, Andrew P. Combs, "Journal of Combinatorial Chemistry (J. Combi. Chem.)", 2004, 6 (6), 874-883, which is incorporated herein by reference in its entirety) and normal phase silica chromatography.

[0208] The known starting materials of the present invention can be synthesized by using or according to methods known in the art, or can be purchased from commercial suppliers. Unless otherwise noted, analytical grade solvents and commercially available reagents were used without further purification.

[0209] Unless otherwise specified, the reactions of the present invention were carried out under a positive pressure of nitrogen or argon or in anhydrous solvents with dried tubes, and the reaction flasks were usually equipped with rubber septa for the introduction of substrates and reagents via syringes. Glassware was oven-dried and / or heat-dried.

[0210] For the purpose of illustration, the general synthetic route for preparing the disclosed compounds and key intermediates is shown below. For a more detailed description of each reaction step, see the following examples section. It will be appreciated by those skilled in the art that other synthetic routes can be used to synthesize the compounds of this invention. Although specific starting materials and reagents are described in the scheme and discussed below, other starting materials and reagents can be easily replaced to provide various derivatives and / or reaction conditions. In addition, according to the present disclosure, many compounds prepared by the following methods can be further modified using conventional chemical methods well known to those skilled in the art.

[0211] General synthetic pathway

[0212] Scheme 1 shows an exemplary synthesis of compounds of formula (I).

[0213]

[0214] Solution 1

[0215] It should be understood that chiral centers in compounds can exist in either the "S" or "R" stereoconfiguration, or as a mixture of the two. Within a molecule, each bond drawn straight from a chiral center includes both (R) and (S) stereoisomers, and mixtures thereof. The compounds of formula (I) provided herein contain a phosphorus chiral center. The isomeric mixture in each of the examples in the Examples section below was separated by HPLC to provide Isomer #a (e.g., Isomer 1a) and Isomer #b (e.g., Isomer 1b). The absolute stereochemistry (R or S) of the phosphorus chiral center in each of the "a" and "b" isomers in the Examples section below has not been determined.

[0216] Uses of Compounds

[0217] In one aspect, the present disclosure provides compounds of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), or pharmaceutically acceptable salts thereof, which can be used as FTC or 3TC prodrugs.

[0218] In some embodiments, the compounds of the present disclosure may be converted into the monophosphate of FTC or 3TC, respectively, after administration, and then metabolized into the triphosphate of FTC or 3TC. In some embodiments, the compounds of the present disclosure may be converted into the monophosphate of FTC or 3TC, respectively, after oral administration, and then metabolized into the triphosphate of FTC or 3TC. In some embodiments, the compounds of the present disclosure may be converted into the monophosphate of FTC or 3TC, respectively, after parenteral administration, and then metabolized into the triphosphate of FTC or 3TC. In some embodiments, the compounds of the present disclosure may be converted into the monophosphate of FTC or 3TC, respectively, in target cells, and then metabolized into the triphosphate of FTC or 3TC. In some embodiments, the compounds of the present disclosure may be converted into the monophosphate of FTC or 3TC, respectively, in human hepatocytes and lymphocytes, and then metabolized into the triphosphate of FTC or 3TC.

[0219] In some embodiments, the compounds of the present disclosure exhibit anti-HIV and anti-HBV activity. In certain embodiments, the compounds of the present disclosure exhibit EC 50 Values ​​of less than 500 nM for anti-HIV and anti-HBV activity as measured according to the assays described in the Examples. In certain embodiments, the compounds of the present disclosure exhibit EC 50 Anti-HIV and anti-HBV activity with values ​​less than 400 nM, 300 nM, 200 nM, 150 nM, 140 nM, 130 nM, 120 nM, 110 nM, 100 nM, 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM or 20 nM as measured according to the assays described in the Examples.

[0220] In some embodiments, the compounds of the present disclosure are more effective than FTC or 3TC in inhibiting HIV or HBV activity. In some embodiments, the compounds of the present disclosure exhibit lower EC values ​​than FTC or 3TC. 50 In certain embodiments, the compounds of the present disclosure exhibit an EC 50 The value is 1 / 2 or 1 / 3 of FTC or 3TC.

[0221] In some embodiments, compounds of the present disclosure are metabolized to FTC or 3TC and phosphates of FTC or 3TC (including monophosphate, diphosphate, and triphosphate) with increased metabolite concentrations compared to those produced by metabolism of FTC or 3TC under the same conditions.

[0222] In certain embodiments, the compounds of the present invention are converted to FTC monophosphate in peripheral blood mononuclear cells (PBMCs) at a concentration higher than the corresponding concentration of FTC monophosphate produced by conversion of the FTC parent drug. In certain embodiments, the compounds of the present disclosure are converted to FTC monophosphate in PBMCs at a concentration more than 1 times, more than 1.5 times, more than 2 times, more than 2.5 times, more than 3 times, more than 3.5 times, more than 4 times, more than 4.5 times, more than 5 times, more than 5.5 times, or more than 6 times the corresponding concentration of FTC monophosphate produced by conversion of the FTC parent drug.

[0223] In certain embodiments, the compounds of the present disclosure are converted to FTC diphosphate in PBMCs at a concentration higher than the corresponding concentration of FTC diphosphate produced by conversion of the FTC parent drug. In certain embodiments, the compounds of the present disclosure are converted to FTC diphosphate in PBMCs at a concentration more than 1 times, more than 1.5 times, more than 2 times, more than 2.5 times, more than 3 times, more than 3.5 times, more than 4 times, more than 4.5 times, more than 5 times, more than 5.5 times, or more than 6 times the corresponding concentration of FTC diphosphate produced by conversion of the FTC parent drug.

[0224] In certain embodiments, the compounds of the present disclosure are converted to FTC triphosphate in PBMCs at a concentration higher than the corresponding concentration of FTC triphosphate produced by the metabolism of the FTC parent drug. In certain embodiments, the compounds of the present disclosure are converted to FTC triphosphate in PBMCs at a concentration more than 1 times, more than 1.5 times, more than 2 times, more than 2.5 times, more than 3 times, more than 3.5 times, more than 4 times, more than 4.5 times, more than 5 times, more than 5.5 times, or more than 6 times the corresponding concentration of FTC triphosphate produced by the conversion of the FTC parent drug.

[0225] In some embodiments, the compounds of the present disclosure are converted to FTC triphosphate in Hep G2 cells at a concentration that is higher than the corresponding concentration of FTC triphosphate produced by conversion of the FTC parent drug after incubation with Hep G2 cells for the same period of time.

[0226] In certain embodiments, after incubation with Hep G2 cells for 1 hour, the compounds of the present disclosure are converted to FTC triphosphate at a concentration that is more than 1 times, more than 2 times, more than 3 times, more than 4 times, more than 5 times, more than 6 times, more than 7 times, more than 8 times, more than 9 times, more than 10 times, more than 11 times, more than 12 times, more than 13 times, more than 14 times, more than 15 times, more than 16 times, more than 17 times, more than 18 times, more than 19 times, more than 20 times, more than 21 times, more than 22 times, more than 23 times, more than 24 times, more than 25 times, more than 26 times, more than 27 times, more than 28 times, more than 29 times, or more than 30 times the corresponding concentration of FTC triphosphate produced by conversion of the FTC parent drug.

[0227] In certain embodiments, after 4 hours of incubation with Hep G2 cells, the compounds of the present disclosure are converted to FTC triphosphate at a concentration that is more than 1 fold, more than 2 fold, more than 3 fold, more than 4 fold, more than 5 fold, more than 6 fold, more than 7 fold, more than 8 fold, more than 9 fold, more than 10 fold, more than 11 fold, more than 12 fold, more than 13 fold, more than 14 fold, more than 15 fold, more than 16 fold, more than 17 fold, more than 18 fold, more than 19 fold, more than 20 fold, more than 21 fold, more than 22 fold, more than 23 fold, more than 24 fold, more than 25 fold, more than 26 fold, more than 27 fold, more than 28 fold, more than 29 fold, more than 30 fold, more than 35 fold, more than 40 fold, more than 45 fold, or more than 50 fold higher than the corresponding concentration of FTC triphosphate produced by conversion of the FTC parent drug.

[0228] In certain embodiments, after 7 hours of incubation with Hep G2 cells, the compounds of the present disclosure are converted to FTC triphosphate at a concentration that is more than 1 fold, more than 2 fold, more than 3 fold, more than 4 fold, more than 5 fold, more than 6 fold, more than 7 fold, more than 8 fold, more than 9 fold, more than 10 fold, more than 11 fold, more than 12 fold, more than 13 fold, more than 14 fold, more than 15 fold, more than 16 fold, more than 17 fold, more than 18 fold, more than 19 fold, more than 20 fold, more than 21 fold, more than 22 fold, more than 23 fold, more than 24 fold, more than 25 fold, more than 26 fold, more than 27 fold, more than 28 fold, more than 29 fold, more than 30 fold, more than 35 fold, more than 40 fold, more than 45 fold, or more than 50 fold higher than the corresponding concentration of FTC triphosphate produced by conversion of the FTC parent drug.

[0229] In certain embodiments, after incubation with Hep G2 cells for 24 hours, the compounds of the present disclosure are converted to FTC triphosphate at a concentration that is more than 1 times, more than 1.5 times, more than 2 times, more than 2.5 times, more than 3 times, more than 3.5 times, more than 4 times, more than 4.5 times, or more than 5 times the corresponding concentration of FTC triphosphate produced by conversion of the FTC parent drug.

[0230] Pharmaceutical composition

[0231] For administration purposes, in some embodiments, the compounds provided herein are administered as the raw chemical substance or formulated into a pharmaceutical composition.

[0232] Therefore, in another aspect, provided herein is a pharmaceutical composition comprising one or more compounds of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), or a pharmaceutically acceptable salt thereof.

[0233] In some embodiments, the pharmaceutical composition of the present invention comprises a compound selected from Formula (I), Formula (Ia), Formula (Ib), Formula (Ic) or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition of the present invention comprises a first compound selected from Formula (I), Formula (Ia), Formula (Ib), Formula (Ic) or a pharmaceutically acceptable salt thereof and one or more other compounds of the same formula, but the first compound and the other compound are not the same molecule.

[0234] As used herein, the term "pharmaceutical composition" refers to a formulation containing a compound of the present invention in a form suitable for administration to a subject.

[0235] In some embodiments, the pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more compounds of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic), or a pharmaceutically acceptable salt thereof.

[0236] As used herein, the term "therapeutically effective amount" refers to the amount of a molecule, compound, or composition comprising the molecule or compound that treats, ameliorates, or prevents an identified disease or condition, or shows a detectable therapeutic or inhibitory effect. The effect can be detected by any analytical method known in the art. The precise effective amount for an individual will depend on the individual's weight, stature, and health; the nature and extent of the condition; the rate of administration; the therapeutic agent or combination of therapeutic agents selected for administration; and the judgment of the prescribing physician. The therapeutically effective amount for a given situation can be determined by routine experiments within the skill and judgment of the clinician.

[0237] In some embodiments, pharmaceutical compositions comprise one or more compounds of the present disclosure, or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable carrier or excipient.

[0238] As used herein, the term "pharmaceutically acceptable excipient" refers to an excipient suitable for preparing a pharmaceutical composition that is generally safe, non-toxic, and biologically and otherwise desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. As used herein, "pharmaceutically acceptable excipient" includes one and more than one such excipient. The term "pharmaceutically acceptable excipient" also encompasses "pharmaceutically acceptable carriers" and "pharmaceutically acceptable diluents." The specific excipient used in the pharmaceutical composition of the present invention will depend on the means and purpose for which the compound of the present invention is to be administered.

[0239] In some embodiments, suitable excipients may include buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; chloride); phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (such as Zn-protein complexes); and / or nonionic surfactants such as TWEEN®. TM 、PLURONICS TM or polyethylene glycol (PEG).

[0240] In some embodiments, suitable excipients may include one or more stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, slip agents, processing aids, colorants, sweeteners, aromatics, flavoring agents and other known additives to provide the best presentation of drugs (i.e., compounds of the present invention or their pharmaceutical compositions) or to help manufacture pharmaceutical products (i.e., medicaments). Active pharmaceutical ingredients may also be coated in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, such as hydroxymethylcellulose or gelatin microcapsules and poly (methyl methacrylate) microcapsules in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in coarse emulsions, respectively. Such technology is disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. Compiled (1980). "Liposomes" are vesicles comprising various types of lipids, phospholipids and / or surfactants, which are suitable for delivering drugs (compounds as disclosed herein and optional chemotherapeutic agents) to mammals (including humans). The components of liposomes are typically arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

[0241] The pharmaceutical compositions of the present disclosure can be prepared by combining one or more compounds provided herein with a suitable pharmaceutically acceptable excipient, and can be in any form that allows the composition to be administered to a subject, including but not limited to humans, and is formulated to be compatible with the intended route of administration.

[0242] In some embodiments, the pharmaceutical compositions of the present disclosure may be in the form of preparations for oral administration, such as tablets, powders, hard gelatin capsules, suspensions in aqueous or non-aqueous liquids, oil-in-water or water-in-oil emulsions, syrups and elixirs, and the like.

[0243] For pharmaceutical compositions in the form of tablet formulations, suitable pharmaceutically acceptable excipients include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate; granulating agents and disintegrants such as corn starch or alginic acid; binders such as starch; lubricants such as magnesium stearate, stearic acid or talc; preservatives such as ethyl or propyl paraben; and antioxidants such as ascorbic acid. Tablet formulations may be uncoated or coated to modulate disintegration and subsequent absorption of the active ingredient in the gastrointestinal tract, or to improve stability and / or appearance, in either case, using conventional coating agents and procedures well known in the art.

[0244] For pharmaceutical compositions in the form of hard gelatin capsules, the active ingredient may be mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin; for soft gelatin capsules, the active ingredient may be mixed with water or oil such as peanut oil, liquid paraffin or olive oil.

[0245] For pharmaceutical compositions in the form of aqueous suspensions, the active ingredient in fine powder form may be mixed with one or more of the following ingredients: a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum arabic; a dispersing or wetting agent, such as lecithin, or a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), or a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetamol), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitan monooleate), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives (for example, ethyl or propyl p-hydroxybenzoate), antioxidants (for example, ascorbic acid), coloring agents, flavoring agents and / or sweetening agents (for example, sucrose, saccharin or aspartame).

[0246] For pharmaceutical compositions in the form of oily suspensions, the active ingredient can be suspended in a vegetable oil (such as peanut oil, castor oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid paraffin). The oily suspension can also contain a thickener, such as beeswax, hard paraffin or cetyl alcohol. Sweeteners (such as those stated above) and flavoring agents can be added to provide a palatable oral formulation. These compositions can be preserved by adding an antioxidant (such as ascorbic acid).

[0247] For pharmaceutical compositions in the form of oil-in-water emulsions, the oil phase may be a vegetable oil, such as olive oil or peanut oil; or a mineral oil, such as liquid paraffin; or a mixture of any of these oils. Suitable emulsifiers may be, for example, naturally occurring gums, such as gum arabic or gum tragacanth; naturally occurring phospholipids, such as soybeans, lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides (e.g., sorbitan monooleate), and condensation products of the partial esters with ethylene oxide (e.g., polyoxyethylene sorbitan monooleate). The emulsion may also contain sweeteners, flavorings, and preservatives.

[0248] For pharmaceutical compositions in the form of syrups and elixirs, sweeteners such as glycerol, propylene glycol, sorbitol, aspartame or sucrose; demulcents; preservatives; flavoring and / or coloring agents may be used.

[0249] In some embodiments, the pharmaceutical composition of the present disclosure can be in the form of a preparation for parenteral administration, such as subcutaneous injection, intravenous, intramuscular or intrasternal injection or infusion. Such parenteral compositions generally use sterile water as a carrier, and optionally use other ingredients, such as dissolution aids. In some embodiments, parenteral compositions can be in the form of sterile injectable preparations, such as sterile injectable aqueous or oily suspensions. The suspension can be prepared according to known techniques using those suitable dispersants or wetting agents and suspending agents mentioned above. The sterile injectable preparation can also be a sterile injectable solution or suspension (such as a solution of 1,3-butanediol) in a non-toxic parenteral acceptable diluent or solvent, or be prepared as a lyophilized powder. For acceptable vehicles and solvents, water, Ringer's solution and isotonic sodium chloride solution, sterile fixed oils (such as synthetic monoglycerides or diglycerides), fatty acids such as oleic acid can be used.

[0250] In some embodiments, the pharmaceutical composition of the present disclosure is an oral formulation. In some embodiments, the pharmaceutical composition of the present disclosure is an injection formulation. In some embodiments, the pharmaceutical composition of the present disclosure is an injection formulation for intramuscular administration.

[0251] In certain embodiments, the pharmaceutical composition of the present invention can be formulated into unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable for use in human individuals and other mammals in a single dose, each unit containing a predetermined amount of active substance calculated to be combined with a suitable pharmaceutical excipient to produce a desired therapeutic effect. The amount of the compound provided herein in unit dosage form will vary according to the condition to be treated, the individual to be treated (e.g., age, body weight, and response of the individual), a specific route of administration, the actual compound administered, and its relative activity and the severity of individual symptoms.

[0252] In some embodiments, the pharmaceutical compositions of the present invention may be in the form of an inhalation formulation. The inhalation formulation may be in the form of an aqueous or non-aqueous (e.g., in a fluorocarbon propellant) aerosol containing any suitable solvent and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH adjusters, surfactants, bioavailability modifiers, and combinations of these. Carriers and stabilizers vary with the requirements of a particular compound, but typically include nonionic surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins (such as serum albumin), sorbitan esters, oleic acid, lecithin, amino acids (such as glycine), buffers, salts, sugars, or sugar alcohols.

[0253] In some embodiments, the pharmaceutical compositions of the present invention may be in the form of topical or transdermal formulations. The topical formulations may be in the form of creams, ointments, gels, and aqueous or oily solutions or suspensions, which may be generally prepared with active ingredients and conventional topically acceptable excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide or mixtures thereof. The transdermal formulations may be prepared in the form of transdermal skin patches well known to those of ordinary skill in the art.

[0254] In some embodiments, for oral administration, each dosage unit contains from about 1 mg to about 1000 mg of one or more compounds provided herein, for example, from about 50 mg to about 1000 mg, from about 100 mg to about 1000 mg, from about 200 mg to 1000 mg, from about 300 mg to about 1000 mg, from about 400 mg to about 1000 mg, from about 500 mg to about 1000 mg, from about 1 mg to 500 mg, from about 10 mg to about 500 mg, from about 50 mg to about 500 mg. g, about 100 mg to about 500 mg, about 200 mg to about 500 mg, about 300 mg to about 500 mg, about 400 mg to about 500 mg, for example, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg or about 500 mg.

[0255] In some embodiments, for parenteral administration, each dosage unit contains about 0.1 mg to about 100 mg of one or more compounds provided herein, e.g., about 0.5 mg to about 100 mg, about 1 mg to about 100 mg, about 5 mg to about 100 mg, about 10 mg to about 100 mg, about 20 mg to about 100 mg, about 30 mg to about 100 mg, about 40 mg to about 100 mg, about 50 mg to about 100 mg, about 0.5 mg to about 90 mg, about 0.5 mg to about 80 mg, about 0.5 mg to about 70 mg, about 0.5 mg to about 60 mg, about 0.5 mg to about 50 mg, about 0.5 mg to about 40 mg, about 1 mg to about 90 mg, about 5 mg to about 90 mg, about 10 mg to about 80 mg, about 20 mg to about 70 mg, about 30 mg to about 60 mg, or about 40 mg to about 50 mg.

[0256] In some embodiments, the dosage level of the pharmaceutical composition of the present disclosure may be between 0.001 mg / kg body weight / day and 1000 mg / kg body weight / day, for example, 0.01 mg / kg body weight / day to 500 mg / kg body weight / day, 0.01 mg / kg body weight / day to 400 mg / kg body weight / day, 0.01 mg / kg body weight / day to 300 mg / kg body weight / day, 0.1 mg / kg body weight / day to 200 mg / kg body weight / day, 0.1-150 mg / kg body weight / day, 0.1 mg / kg body weight / day to 100 mg / kg body weight / day, 0.5 mg / kg body weight / day to 10 In some cases, dosage levels below the lower limit of the above range may be sufficient, while in other cases, larger dosages may still be used without causing any harmful side effects, as long as this larger dosage is first divided into several small doses for administration throughout the day. For further information on routes of administration and dosage regimens, see Volume 5, Chapter 25.3 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press, 1990, which is expressly incorporated herein by reference.

[0257] Due to the improved stability of the compounds provided herein, the pharmaceutical compositions of the present disclosure may be long-acting formulations.

[0258] In some embodiments, the pharmaceutical composition of the invention administered to a subject is active for at least 10 days, at least 15 days, at least 30 days, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months. In some embodiments, the pharmaceutical composition of the invention administered to a subject is active for up to 6 months, up to 5 months, up to 4 months, up to 3 months, up to 2 months, or up to 1 month.

[0259] Therefore, the favorable stability of the compounds provided herein can make the compounds and pharmaceutical compositions comprising the compounds suitable for less frequent administration. For example, dosing regimens with longer time intervals include but are not limited to administration every two weeks, every month, every two months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months or every 12 months.

[0260] In some embodiments, the pharmaceutical compositions of the present disclosure are formulated for parenteral administration, e.g., intravenous or intramuscular administration via injection at long-duration dosing intervals such as every month, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, yearly, or longer. The dosage may be adjusted upward as needed to provide effective treatment within the time interval between each dosage administration.

[0261] In some embodiments, pharmaceutical compositions intended for administration by injection may be prepared by combining one or more compounds of the invention with sterile distilled water to form a solution. In some embodiments, the pharmaceutical composition may include a surfactant or other dissolving excipient, which is added to facilitate the formation of a homogeneous solution or suspension. In some embodiments, the pharmaceutical composition may further include one or more additional agents selected from the group consisting of a wetting agent, a suspending agent, a preservative, a buffer, and an isotonic agent.

[0262] In certain embodiments, the pharmaceutical composition intended to be administered by injection can be administered with a syringe. In certain embodiments, the syringe is disposable. In certain embodiments, the syringe is reusable. In certain embodiments, the syringe is pre-filled with a pharmaceutical composition provided herein.

[0263] In some embodiments, the pharmaceutical composition of the present invention comprising one or more compounds of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic) or pharmaceutically acceptable salts thereof further comprises one or more additional agents. In some embodiments, these additional agents are selected from antiviral agents, immunotherapeutic agents or anti-infective agents.

[0264] In some embodiments, the additional antiviral agent may be an anti-HBV agent or an anti-HIV agent.

[0265] In some embodiments, the anti-HBV agent is selected from HBV DNA polymerase inhibitors, HBV replication inhibitors, HBV RNAse inhibitors, HBV viral entry inhibitors, HBV combination drugs, HBV vaccines, HBV E antigen inhibitors, HBV antibodies, non-HBV nucleoside reverse transcriptase inhibitors, HBV nucleoside reverse transcriptase inhibitors, HBV fusion inhibitors, HBV capsid inhibitors, HBV core protein assembly regulators, HBV cccDNA inhibitors, HBV X protein inhibitors and RNA interference compounds.

[0266] Examples of HBV replication inhibitors include isothiafludine, IQP-HBV, RM-5038, and Xingantie.

[0267] Examples of HBV viral entry inhibitors include Myrcludex B.

[0268] Examples of HBV combination drugs include ABX-203, lamivudine, and INO-1800.

[0269] HBV vaccines include both preventive vaccines and therapeutic vaccines. Examples of HBV preventive vaccines include Vaxelis, Hexaxim, Heplisav, Mosquirix, DTwP-HBV vaccine, Bio-Hep-B, D / T / P / HBV / M (LBVP-0101; LBVW-0101), DTwP-Hepb-Hib-IPV vaccine, Heberpenta L, DTwP-HepB-Hib, V-419, CVI-HBV-001, Tetrabhay, Hepatrol-07, GSK-223192A, Recombinant Hepatitis B Vaccine, Recombinant Hepatitis B Surface Antigen Vaccine, Bimmugen, Euforavac, Eutravac, anrix-DTaP-IPV-Hep B, HBAI-20, Infanrix-DTaP-IPV-Hep B-Hib, Pentabio Vaksin DTP-HB-Hib, Comvac 4, Twinrix, Euvax-B, Tritanrix HB, Infanrix Hep B, Comvax, DTP-Hib-HBV Vaccine, DTP-HBV Vaccine, YiTai, Heberbiovac HB, Trivac HB, GerVax, DTwP-Hep B-Hib Vaccine, Bilive, Hepavax-Gene, SUPERVAX, Comvac5, Shanvac-B, Hebsulin, Recombivax HB, Revac B mcf, Revac B+, Fendrix, DTwP-HepB-Hib, DNA-001, Shan6, rhHBsAG vaccine and DTaP-rHB-Hib vaccine. Examples of HBV therapeutic vaccines include HBsAG-HBIG complex, ARB-1598, Bio-Hep-B, NASVAC, abi-HB (intravenous injection), ABX-203, Tetrabhay, GX-110E, GS-4774, peptide vaccine (epsilonPA-44), Hepatrol-07, NASVAC (NASTERAP), IMP-321, BEVAC, Revac B mcf, MGN-1333, KW-2, CVI-HBV-002, AltraHepB, VGX-6200, FP-02, FP-02.2, TG-1050, NU-500, HBV ax, im / TriGrid / antigen vaccine, Mega-CD40L-adjuvant vaccine, HepB-v, RG7944 (INO-1800), AdTG-17909, AdTG-17910AdTG-18202, ChronVac-B, TG-1050 and Lm HBV.

[0270] Examples of HBV E antigen inhibitors include wogonin.

[0271] Examples of HBV antibodies include Zutectra, Shang Sheng Gan Di, Uman Big (hepatitis B hyperimmune), Omri-Hep-B, Nabi-HB, Hepatect CP, HepaGam B, igantibe, Niuliva, CT-P24, hepatitis B immune globulin (intravenous injection, pH4, HBV infection, Shanghai RAAS blood products) and Fovepta (BT-088).

[0272] In some embodiments, the anti-HIV agent is selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors, HIV entry inhibitors, HIV maturation inhibitors, and HIV capsid inhibitors.

[0273] Examples of HIV protease inhibitors include amprenavir, atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tipranavir, DG-17, TMB-657 (PPL-100), T-169, BL-008, and TMC-310911.

[0274] Examples of HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase include dapivirine, delavirdine, delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan, nevirapine, rilpivirine, AIC-292, KM-023, and VM-1500.

[0275] Examples of HIV nucleoside or nucleotide inhibitors of reverse transcriptase include adefovir, adefovir dipivoxil, azithromycin, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir disoproxil hemifumarate, and (didanosine, ddl), abacavir, abacavir sulfate, alovudine, aritibactam, sinavudine, didanosine, efavirenz, fostavudine ester, CMX-157, dapivirine, doravirine, etravirine, OCR-5753, tenofovir disoproxil orotate, fostavudine ester, lamivudine, phosphinothricin, stavudine, zalcitabine, zidovudine, GS-9131, GS-9148 and KP-1461.

[0276] Examples of HIV integrase inhibitors include elvitegravir, curcumin, a derivative of curcumin, chicoric acid, a derivative of chicoric acid, 3,5-dicaffeoylquinic acid, a derivative of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, a derivative of aurintricarboxylic acid, caffeic acid phenethyl ester, a derivative of caffeic acid phenethyl ester, a tyrosine kinase inhibitor, a derivative of a tyrosine kinase inhibitor, quercetin, a derivative of quercetin, raltegravir, dolutegravir, JTK-351, bicagvir, AVX-155 67. Cabotegravir (long-acting injectable form), diketoquinoline-4-1 derivatives, integrase-LEDGF inhibitors, ledgins, M-522, M-532, NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, distilbenesulphonic acid, T-169 and cabotegravir.

[0277] Examples of HIV entry (fusion) inhibitors include cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 attachment inhibitors, gpl20 inhibitors, and CXCR4 inhibitors.

[0278] Examples of HIV maturation inhibitors include BMS-955176 and GSK-2838232.

[0279] Examples of HIV capsid inhibitors include HIV nucleocapsid p7 (NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein inhibitors, AVI-621, AVI-101, AVI-201, AVI-301 and AVI-CAN1-15 series.

[0280] In some embodiments, the immunotherapeutic agent is selected from a Toll-like receptor modulator, a programmed cell death protein 1 (PD-1) modulator, a programmed death ligand 1 (PD-L1) modulator, an interferon, and a pegylated interferon.

[0281] Examples of Toll-like receptor modulators include tlr1, tlr2, tlr3, tlr4, tlr5, tlr6, tlr7, tlr8, tlr9, tlr10, tlr11, tlr12, and tlr13.

[0282] Examples of PD-1 modulators include nivolumab, pembrolizumab, pidilizumab, BGB-108, SHR-1210, PDR-001, PF-06801591, IBI-308, GB-226, STI-1110, and mDX-400.

[0283] Examples of PD-L1 modulators include atezolizumab, avelumab, AMP-224, MEDI-0680, RG-7446, GX-P2, durvalumab, KY-1003, KD-033, MSB-0010718C, TSR-042, ALN-PDL, STI-A1014, CX-072, and BMS-936559.

[0284] Examples of interferons and pegylated interferons include interferon α, interferon α-2b, interferon α-n3, interferon γ, pegylated interferon α, pegylated interferon α-2a, and pegylated interferon α-2b.

[0285] In some embodiments, the anti-infective agent is selected from an antifungal agent and an antibacterial agent.

[0286] The pharmaceutical composition of the present disclosure can be packaged in various ways according to the method for administering the drug. For example, the article for distribution can include a container in which the pharmaceutical composition in an appropriate form is deposited. Suitable containers are well known to those skilled in the art, including materials such as bottles (plastic and glass), pouches, ampoules, plastic bags, metal cylinders, vials, jars, preloaded syringes, intravenous bags, etc. The container may also include a tamper-proof assembly to prevent inadvertent contact with the contents of the package. In addition, a label describing the contents of the container is placed on the container. The label may also include appropriate warnings. The composition may also be packaged in unit dose or multi-dose containers, such as sealed ampoules and vials, and may be stored under freeze drying (lyophilization) conditions, requiring only the addition of a sterile liquid carrier (e.g., water) immediately before use for injection. Extemporaneous injection solutions and suspensions are prepared by sterile powders, granules, and tablets of the aforementioned types.

[0287] Therefore, in another aspect, a kit is provided, comprising a compound of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described herein, and suitable packaging. In some embodiments, the kit further comprises instructions for use.

[0288] In another aspect, a product is provided, comprising a compound of Formula (I), Formula (Ia), Formula (Ib), Formula (Ic) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described herein, provided in a suitable container. In some embodiments, the container can be a bottle (plastic and glass), a pouch, an ampoule, a plastic bag, a metal cylinder, a vial, a jar, a preloaded syringe, or an intravenous bag.

[0289] Methods of treating diseases

[0290] In another aspect, provided is a method for preventing or treating a viral infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein.

[0291] In some embodiments, the viral infection is HBV infection.

[0292] In some embodiments, the viral infection is HIV infection.

[0293] In some embodiments, the subject is at risk for HBV infection, such as a subject having one or more risk factors known to be associated with infection with the hepatitis B virus.

[0294] In some embodiments, the subject is at risk for HIV infection, such as a subject having one or more risk factors known to be associated with infection with the HIV virus.

[0295] In some embodiments, the subject may not have previously received antiviral therapy (treatment naive). In some embodiments, the subject may have previously received antiviral therapy (treatment experienced). In some embodiments, the subject may have previously received antiviral therapy and developed resistance to the previously received antiviral therapy.

[0296] In some embodiments, the compounds or pharmaceutical compositions of the present disclosure may be administered as a single active agent. In some embodiments, the compounds or pharmaceutical compositions of the present disclosure may be administered in combination with one or more additional active ingredients. Those skilled in the art will recognize that a variety of active ingredients may be combined with the compounds of the present disclosure. In some embodiments, the additional active ingredients of the pharmaceutical combination formulation or dosing regimen have an activity complementary to the compounds of the present disclosure so that they do not adversely affect each other. Such ingredients are appropriately combined in an amount effective for the intended purpose.

[0297] In some embodiments, the method of preventing or treating a viral infection in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein in combination with one or more additional therapeutic agents. In some embodiments, these additional therapeutic agents are selected from the above-mentioned antiviral agents, immunotherapeutic agents, and anti-infective agents.

[0298] In some embodiments, the compounds of the present disclosure may be administered simultaneously, sequentially, or separately with the additional therapeutic agent.

[0299] In yet another aspect, a method for preventing or treating a viral infection in a subject in need thereof is provided, the method comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition provided herein and one or more additional therapeutic agents simultaneously, sequentially or separately.

[0300] Examples

[0301] For illustrative purposes, the following examples are included. However, it should be understood that these examples do not limit the present invention and are intended only to illustrate methods of practicing the present invention. Those skilled in the art will recognize that the chemical reactions described may be easily applicable to the preparation of a variety of other compounds of the present invention, and alternative methods for preparing the compounds of the present invention are considered to be within the scope of the present invention. For example, non-exemplary compounds according to the present invention may be successfully synthesized by modifications apparent to those skilled in the art, such as by appropriately protecting interfering groups, by utilizing other suitable reagents and building blocks known in the art in addition to the reagents and building blocks, and / or by routinely changing reaction conditions. Alternatively, other reactions disclosed herein or known in the art will be considered to be applicable to the preparation of other compounds of the present invention.

[0302] General methods and conditions

[0303] LCMS conditions:

[0304] Instrument: Shimadzu equipped with LC20AD pump and PDA detector; Column: Restek Ultra C18 (50 mm×2.1 mm×5.0 μm); Mobile phase: 0.1% HCOOH in H2O / ACN; Gradient: ACN from 5% to 95% in 0.1 min to 2.5 min, ACN is 95% in 2.5 min to 3.0 min, ACN is from 95% to 98% in 3.0 min to 4.0 min, ACN is from 98% to 5% in 4.0 min to 4.15 min, ACN is 5% in 4.15 min to 4.55 min; Column temperature: 25°C; Detection wavelength: 214 / 254 nm; Flow rate: 1.0 mL / min; Injection volume: 5 μL.

[0305] HPLC analysis conditions:

[0306] Instrument: Agilent 1200 system with DAD detector; Column: Kinetex 5u EVO C18 (150mm×4.6mm); mobile phase: 0.1% TFA in H2O / ACN solution; gradient: ACN from 5% to 95% within 0.1 min to 7.5 min, ACN from 7.5 min to 9.5 min is 95%, ACN from 95% to 5% within 9.5 min to 10 min; column temperature: 25°C; detection wavelength: 214 / 254nm; flow rate: 1.0mL / min; injection volume: 5μL.

[0307] Chiral HPLC analysis conditions:

[0308] Instrument: Agilent 1200 system with DAD; column: Daicel AD-H (250 mm×4.6 mm×5.0 μm); mobile phase: hexane:IPA:MeOH=80:15:5, 0.1% DEA; column temperature: 35°C; detection wavelength: 214 / 254 nm; flow rate: 1.0 mL / min; run time: 30 min.

[0309] Preparative HPLC (normal phase) conditions:

[0310] Instrument: Varian PREP-HPLC system; Column: Uni Silica (250 mm × 21.2 × 10 μm, ); mobile phase and gradient: DCM:MeOH=97:3 to 90:10 within 20 minutes; column temperature: 25°C; detection wavelength: 214 / 254nm; flow rate: 20mL / min; injection volume: 0.5mL (sample concentration 50mg / mL).

[0311] Preparative HPLC (reverse phase) conditions:

[0312] Method A: Instrument: Shimadzu LC8AP PREP-HPLC system; Column: Boston ODS (250 mm × 21.2 mm × 10 μm, ); mobile phase: 0.1% TFA in H2O / ACN; gradient: 5% ACN from 1 min to 5 min, 5% to 25% ACN from 5 min to 20 min, 25% ACN from 20 min to 25 min; column temperature: 25°C; detection wavelength: 214 / 254 nm; flow rate: 20 mL / min; injection volume: 1 mL (sample concentration 50 mg / mL).

[0313] Method B: Instrument: Shimadzu LC8AP PREP-HPLC system; Column: Boston ODS (250 mm × 21.2 mm × 10 μm, ); mobile phase: 0.1% TFA in H2O / ACN; gradient: 5% ACN from 1 min to 5 min, 10% to 30% ACN from 5 min to 20 min, 25% ACN from 20 min to 25 min; column temperature: 25°C; detection wavelength: 214 / 254 nm; flow rate: 20 mL / min; injection volume: 1 mL (sample concentration 50 mg / mL).

[0314] Method C: Instrument: Shimadzu LC8AP PREP-HPLC system; Column: Boston ODS (250 mm × 21.2 mm × 10 μm, ); mobile phase: 0.1% TFA in H2O / ACN; gradient: 5% ACN from 1 min to 5 min, 20% to 50% ACN from 5 min to 20 min, 25% ACN from 20 min to 25 min; column temperature: 25°C; detection wavelength: 214 / 254 nm; flow rate: 20 mL / min; injection volume: 1 mL (sample concentration 50 mg / mL).

[0315] Chiral preparative HPLC conditions:

[0316] Instrument: Shimadzu LC8AP PREP-HPLC system; column: Daicel AD-H Semi-Prep (250 mm×10.0 mm×5.0 μm); mobile phase: hexane:IPA:MeOH=80:15:5, 0.1% DEA; column temperature: 35°C; detection wavelength: 214 / 254 nm; flow rate: 5.0 mL / min; run time: 15 min.

[0317] Example 1

[0318] Synthesis of compounds 5a and 5b

[0319]

[0320] To a solution of 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one (500 mg, 2 mmol, 1.0 eq) in THF (10 mL) was added TEA (265.5 mg, 2.6 mmol, 1.3 eq) at 0°C, and the mixture was stirred under N2 and 0°C for 0.5 hours. Then POCl3 (398.7 mg, 2.6 mmol, 1.3 eq) was added to the reaction mixture at -78°C, and the mixture was stirred at 0°C for 1 hour. Then 5-3 (322.5 mg, 2 mmol, 1.0 eq) and TEA (606 mg, 6 mmol, 3 eq) were added to the mixture at -78°C, and the mixture was stirred at 0°C for 1 hour. Then 5-4 (787 mg, 6 mmol, 3.0 equivalents) and TEA (2.02 g, 20 mmol, 10 equivalents) were added to the mixture at -78 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (40 mL) and extracted with ethyl acetate (20 mL×3), and the combined organic layer was washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93%:7%) to obtain compound 5 (136 mg), which was separated by chiral HPLC to obtain compound 5a (39.5 mg) and compound 5b (36.8 mg).

[0321] Compound 5a:

[0322] LCMS: Rt = 2.188 min; m / z = 584 [M+1] + ;

[0323] 1 H NMR (400MHz, CDCl3) δ7.98(d,J=6.3Hz,1H),7.29(t,J=7.4Hz,2H),7.18(t,J=8.8 Hz,3H),6.30(s,1H),5.34(s,1H),4.41-4.33(m,1H),4.30(s,1H),4.17(q,J=7.1H z,2H),3.76(s,2H),3.66(d,J=8.9Hz,1H),3.55(m,1H),3.10(m,1H),2.77(s,2H) ,2.60(s,1H),1.82(m,3H),1.67-1.57(m,2H),1.54(m,6H),1.26(t,J=7.1Hz,3H).

[0324] Compound 5b:

[0325] LCMS: Rt = 2.173 min; m / z = 584 [M+1] + ;

[0326] 1 H NMR (400MHz, CDCl3) δ7.98 (d, J=6.3Hz, 3H), 7.29 (t, J=7.4Hz, 7H), 7.18 (t, J= 9.6Hz,11H),6.30(s,3H),5.35(s,4H),4.39-4.25(m,6H),4.18(q,J=7.1Hz,7H ),3.77(s,7H),3.59-3.50(m,7H),3.12(m,3H),2.77(s,7H),2.60(s,3H),1.82 (m,9H),1.78-1.68(m,5H),1.61(s,8H),1.55(m,23H),1.27(t,J=7.1Hz,13H).

[0327] Example 2

[0328] Synthesis of compounds 6a and 6b

[0329]

[0330] To a solution of 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one (500 mg, 2 mmol, 1.0 eq) in THF (10 mL) was added TEA (265.5 mg, 2.6 mmol, 1.3 eq) at 0°C, and the mixture was stirred under N2 and 0°C for 0.5 hours. Then POCl3 (398.7 mg, 2.6 mmol, 1.3 eq) was added to the reaction mixture at -78°C, and the mixture was stirred at 0°C for 1 hour. Then 6-3 (322.5 mg, 2 mmol, 1.0 eq) and TEA (606 mg, 6 mmol, 3 eq) were added to the mixture at -78°C, and the mixture was stirred at 0°C for 1 hour. Then 6-4 (787 mg, 6 mmol, 3.0 equivalents) and TEA (2.02 g, 20 mmol, 10 equivalents) were added to the mixture at -78 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (40 mL) and extracted with ethyl acetate (20 mL × 3), and the combined organic layer was washed with brine (20 mL × 3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93%:7%) to obtain compound 6 (119 mg), which was separated by chiral HPLC to obtain compound 6a (54.8 mg) and compound 6b (42.7 mg).

[0331] Compound 6a:

[0332] LCMS: Rt = 2.267 min; m / z = 584 [M+1] + ;

[0333] 1 H NMR (400MHz, CDCl3) δ8.00(d,J=6.3Hz,1H),7.71(s,1H),7.29(t,J=7.5Hz,2H),7.18(m,3 H),6.30(m,1H),5.73(s,1H),5.34(m,1H),4.42-4.33(m,1H),4.31-4.24(m,1H),4.17(m, 2H),3.88(m,1H),3.74(s,2H),3.53(m,1H),3.26(m,1H),3.09(m,1H),2.80(m,2H),2.61( m,1H),1.87-1.67(m,4H),1.66-1.52(m,2H),1.25(t,J=7.1Hz,3H),0.91(t,J=7.4Hz,3H).

[0334] Compound 6b:

[0335] LCMS: Rt = 2.200 min; m / z = 584 [M+1] + ;

[0336] 1 H NMR(400MHz, CDCl3)δ7.98(m,1H),7.64(s,1H),7.28(m,2H),7.18(m,3H),6 .29(s,1H),5.72(s,1H),5.32(s,1H),4.44-4.27(m,2H),4.17(m,2H),3.76( m,3H),3.51(m,2H),3.13(m,1H),2.80(s,2H),2.60(s,1H),2.00(m,2H),1.8 6-1.70(m,4H),1.67-1.49(m,2H),1.28-1.21(m,4H),0.96(t,J=6.6Hz,3H).

[0337] Example 3

[0338] Synthesis of compounds 7a and 7b

[0339]

[0340] To a solution of 7-1 (2 g, 8 mmol, 1.0 equiv) in anhydrous THF (30 mL) was added TEA (980 mg, 9.7 mmol, 1.2 equiv) at room temperature and N2. After stirring for 30 minutes, POCl3 (1.487 g, 9.7 mmol, 1.2 equiv) was added to the reaction mixture at -78°C and N2, and the solution was then stirred at -78°C for 0.5 hours. To the above solution was added dropwise a mixture of 7-3 (1.955 g, 12 mmol, 1.5 equiv), 7-4 (1.955 g, 12 mmol, 1.5 equiv) and TEA (8.16 g, 80 mmol, 10 equiv) in THF (10 mL) at 0°C and N2, and the mixture was then stirred at room temperature for 30 minutes. The reaction mixture was quenched with H2O (150 mL) and extracted with DCM (50 mL×3), and the combined organic layers were washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=10:1) to give compound 7 (374.1 mg, 8.1% yield), which was separated by chiral HPLC to give compound 7a (154.8 mg) and compound 7b (106.2 mg).

[0341] Compound 7:

[0342] LCMS: Rt = 2.067 min; m / z = 570. [M+1] + ;

[0343] 1 H NMR (400MHz, CDCl3) δ8.13 (s, 0H), 7.98 (d, J = 6.2Hz, 1H), 7.29 (t, J = 6.5Hz, 2H), 7.18(t,J=8.3Hz,3H),6.29(s,1H),5.94(s,1H),5.33(d,J=3.0Hz,1H),4.33(m, 2H),4.16(m,2H),3.93(m,1H),3.74(s,2H),3.45(m,2H),3.11(m,1H),2.81(s,2 H),2.59(d,J=11.9Hz,1H),1.81(s,2H),1.59(m,2H),1.41(m,3H),1.24(m,4H).

[0344] Example 4

[0345] Synthesis of compounds 8a and 8b

[0346]

[0347] To a solution of 8-1 (2 g, 8 mmol, 1.0 equiv) in anhydrous THF (30 mL) was added TEA (980 mg, 9.7 mmol, 1.2 equiv) at room temperature and N2. After stirring for 30 minutes, POCl3 (1.487 g, 9.7 mmol, 1.2 equiv) was added to the reaction mixture at -78°C and N2, and the solution was then stirred at -78°C for 0.5 hours. To the above solution was added dropwise a mixture of 8-3 (1.955 g, 12 mmol, 1.5 equiv), 8-4 (1.955 g, 12 mmol, 1.5 equiv) and TEA (8.16 g, 80 mmol, 10 equiv) in THF (10 mL) at 0°C and N2, and the mixture was then stirred at room temperature for 30 minutes. The reaction mixture was quenched with H2O (150 mL) and extracted with DCM (50 mL×3), the combined organic layers were washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=10:1), which was purified by preparative HPLC (ACN:H2O=35%+0.1% TFA) to give compound 8 (615 mg, 12% yield), which was separated by chiral HPLC to give compound 8a (304.5 mg) and compound 8b (207.2 mg).

[0348] Compound 8:

[0349] LCMS: Rt = 2.333 min; m / z = 598. [M+1] + ;

[0350] 1 H NMR (400MHz, CDCl3) δ8.30(d,J=6.2Hz,1H),7.95(m,0H),7.30(t,J=7.2Hz,2H),7.20( d,J=10.6Hz,3H),6.27(s,1H),5.36(s,1H),4.35(d,J=25.6Hz,1H),4.10(m,2H),3.88 (s,1H),3.74(s,2H),3.56(d,J=7.7Hz,1H),3.33(s,1H),3.22(s,1H),2.82(s,3H),2. 63(s,1H),1.82(s,2H),1.59(d,J=7.1Hz,4H),1.42(m,3H),1.35(s,2H),0.90(m,3H).

[0351] Example 5

[0352] Synthesis of compounds 9a and 9b

[0353]

[0354] To a solution of 9-1 (600 mg, 2.427 mmol, 1.0 equiv) in anhydrous THF (10 mL) was added TEA (294.6 mg, 2.912 mmol, 1.2 equiv) at room temperature, and the mixture was stirred at room temperature for 30 min, and then POCl3 (446.5 mg, 2.912 mmol, 1.2 equiv) was added at -78°C. After 30 minutes, 4-phenoxypiperidine (429.5 mg, 2.427 mmol, 1.0 equiv), ethyl 2-amino-2-methylpropanoate (611.6 mg, 3.640 mmol, 1.5 equiv) and TEA (2451.2 mg, 24.27 mmol, 10.0 equiv) in THF (10 mL) were added dropwise at 0°C and N2 to the above solution, and then the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (10 mL) and extracted with DCM (15 mL×3), and the combined organic layers were washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=94:6) to give compound 9 (107.8 mg, 7.4% yield), which was separated by chiral HPLC to give compound 9a (41.6 mg) and compound 9b (33.2 mg).

[0355] Compound 9:

[0356] LCMS: Rt = 2.25 min; m / z = 600 [M+1] + ;

[0357] 1 H NMR(400MHz, CDCl3)δ8.01-7.91(m,1H),7.50(brs,1H),7.27-7.22(m,2H),6 .96-6.80(m,3H),6.29(s,1H),5.63(brs,1H),5.33(s,1H),4.45-4.22(m,3H) ,4.21-4.11(m,2H),3.74-3.62(m,1H),3.58-3.40(m,3H),3.15-2.97(m,3H) ,1.99-1.88(m,2H),1.78-1.64(m,2H),1.56-1.47(m,6H),1.27-1.21(m,3H).

[0358] Example 6

[0359] Synthesis of compounds 10a and 10b

[0360]

[0361] To a solution of 10-1 (700 mg, 2.831 mmol, 1.0 equiv) in anhydrous THF (10 mL) was added TEA (343.7 mg, 3.397 mmol, 1.2 equiv) at room temperature, and the mixture was stirred at room temperature for 30 min, and then POCl3 (520.9 mg, 3.397 mmol, 1.2 equiv) was added at -78°C. After 30 minutes, 4-phenoxypiperidine (501.1 mg, 2.831 mmol, 1.0 equiv), (R)-ethyl 2-aminobutyrate (713.4 mg, 4.25 mmol, 1.5 equiv) and TEA (2859.3 mg, 28.31 mmol, 10.0 equiv) in THF (10 mL) were added dropwise at 0°C and N2 to the above solution, and then the mixture was stirred at room temperature for 48 hours. The reaction mixture was quenched with H2O (10 mL) and extracted with DCM (15 mL×3), and the combined organic layers were washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=94:6) to give compound 10 (169.5 mg, 10% yield), which was separated by chiral HPLC to give compound 10a (66.3 mg) and compound 10b (45.3 mg).

[0362] Compound 10:

[0363] LCMS: Rt = 1.95 min; m / z = 600 [M+1] + ;

[0364] 1 H NMR (400MHz, CDCl3) δ7.96-7.89(m,1H),7.49-7.29(m,1H),7.23-7.18(m,3H),6.91-6.84(m ,1H),6.84-6.79(m,2H),6.27-6.20(m,1H),5.64(brs,1H),5.31-5.24(m,1H),4.41-4.27(m, 2H),4.27-4.03(m,3H),3.86-3.68(m,1H),3.52-3.36(m,3H),3.32(t,J=10.3Hz,1H),3.21( t,J=9.9Hz,1H),3.11-2.94(m,3H),1.75-1.58(m,4H),1.22-1.16(m,4H),0.92-0.82(m,3H).

[0365] Example 7

[0366] Synthesis of compounds 11a and 11b

[0367]

[0368] To a solution of 11-1 (1 g, 4.04 mmol, 1.0 equiv) in anhydrous THF (15 mL) was added TEA (531 mg, 5.26 mmol, 1.3 equiv) at 0°C and N2. After stirring for 1 hour, POCl3 (806 mg, 5.26 mmol, 1.3 equiv) was added to the reaction mixture at -78°C and N2, and the solution was stirred at -78°C for 1 hour. To the above solution was added dropwise a mixture of 11-3 (785 mg, 6.07 mmol, 1.5 equiv), 11-4 (1.6 g, 12.13 mmol, 3.0 equiv) and TEA (2.86 g, 28.30 mmol, 7.0 equiv) in THF (10 mL) at 0°C and N2, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (25 mL×3), and the combined organic layers were washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=96:4) to give compound 11 (104 mg, 4% yield), which was separated by chiral HPLC to give compound 11a (43.8 mg) and compound 11b (31.5 mg).

[0369] Compound 11:

[0370] LCMS: Rt = 2.067 min; m / z = 552 [M+1] + ;

[0371] 1 H NMR (400MHz, CDCl3) δ7.96(d,J=5.9Hz,0.5H),7.89(d,J=6.4Hz,0.5H),7.62(s,0.5H),6.27(s,1H),5.61(s,0.5H),5.31(s,1H),4.32(m, 1H),4.16(m,3H),3.46(m,2H),3.07(m,1H),2.99(dd,J=16.1,10.8Hz,4H),1.50(m,6H),1.42(m,4H),1.25(m,7H),0.89(t,J=7.3Hz,6H).

[0372] Example 8

[0373] Synthesis of compounds 12a and 12b

[0374]

[0375] To a solution of 12-1 (1 g, 4.04 mmol, 1.0 equiv) in anhydrous THF (15 mL) was added TEA (531 mg, 5.26 mmol, 1.3 equiv) at 0°C and N2. After stirring for 1 hour, POCl3 (806 mg, 5.26 mmol, 1.3 equiv) was added to the reaction mixture at -78°C and N2, and the solution was stirred at -78°C for 1 hour. To the above solution was added dropwise a mixture of 12-3 (3.6 g, 28.28 mmol, 4.0 equiv), 12-4 (530 mg, 4.04 mmol, 1.0 equiv) and TEA (2.86 g, 28.30 mmol, 7.0 equiv) in THF (10 mL) at 0°C and N2, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (25 mL×3), the combined organic layers were washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by preparative HPLC to give compound 12 (133 mg, 6% yield), which was separated by chiral HPLC to give compound 12a (61.1 mg) and compound 12b (52.6 mg).

[0376] Compound 12:

[0377] LCMS: Rt = 2.033 min; m / z = 552 [M+1] + ;

[0378] 1 H NMR (400MHz, CDCl3) δ7.99(d,J=6.3Hz,0.5H),7.91(d,J=6.4Hz,0.5H),7.52(s,0.5H),6.27(m,1H),5.57(s,1H) ,5.31(s,1H),4.31(m,1H),4.17(m,3H),3.81(m,1H),3.52(m,1H),3.12(m,2H),2.97(m,4H),1.72(m,2H),1.46(m 4H), 1.24 (t, J = 7.1Hz, 7H), 0.88 (m, 9H).

[0379] Example 9

[0380] Synthesis of compounds 13a and 13b

[0381]

[0382] To a solution of 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one (500 mg, 2 mmol, 1.0 eq) in THF (10 mL) was added TEA (265.5 mg, 2.6 mmol, 1.3 eq) at 0°C, and the mixture was stirred under N2 and 0°C for 0.5 h. POCl3 (398.7 mg, 2.6 mmol, 1.3 eq) was then added to the reaction mixture at -78°C, and the mixture was stirred at 0°C for 1 h. 13-4 (314.8 mg, 2.4 mmol, 1.2 eq) and TEA (606 mg, 6 mmol, 3 eq) were then added to the mixture at -78°C, and the mixture was stirred at 0°C for 1 h. Then 13-3 (319.7 mg, 2.4 mmol, 1.2 equivalents) and TEA (2.02 g, 20 mmol, 10 equivalents) were added to the mixture at -78 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (40 mL) and extracted with ethyl acetate (20 mL×3), and the combined organic layer was washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93%:7%) to obtain compound 13 (89 mg), which was separated by chiral HPLC to obtain compound 13a (47.1 mg) and compound 13b (14.5 mg).

[0383] Compound 13a:

[0384] LCMS: Rt = 2.411 min; m / z = 556 [M+1] + ;

[0385] 1 H NMR (400MHz, CDCl3) δ9.44(s,1H),7.91(d,J=6.6Hz,1H),7.14-7.08(m,3H),7.01(s,1H),6.23(s,1H),5.49(s,1H),5.24(s,1H),4.3 2(m,3H),4.15(m,-3H),3.70(d,J=8.7Hz,1H),3.53-3.36(m,3H),3.00(m,1H),2.82(m,2H),1.50(m,-6H),1.42(m,1H),1.25(m,3H).

[0386] Compound 13b:

[0387] LCMS: Rt = 2.360 min; m / z = 556 [M+1] + ;

[0388] 1 H NMR (400MHz, CDCl3) δ7.89(d,J=6.3Hz,1H),7.14-7.06(m,3H),7.00(s,1H),6.20(s,1H),5.77(s,1H),5.27(d,J=9.7Hz,1H),4.36-4.24( m,3H),4.23-4.11(m,3H),3.56(d,J=9.0Hz,1H),3.48(m,3H),3.03(m,1H),2.82(s,2H),1.51(m,6H),1.25(d,J=7.1Hz,4H),0.86(s,1H).

[0389] Example 10

[0390] Synthesis of compounds 14a and 14b

[0391]

[0392] To a solution of 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one (500 mg, 2 mmol, 1.0 eq) in THF (10 mL) was added TEA (265.5 mg, 2.6 mmol, 1.3 eq) at 0°C, and the mixture was stirred under N2 and 0°C for 0.5 h. POCl3 (398.7 mg, 2.6 mmol, 1.3 eq) was then added to the reaction mixture at -78°C, and the mixture was stirred at 0°C for 1 h. 14-3 (266.38 mg, 2 mmol, 1 eq) and TEA (606 mg, 6 mmol, 3 eq) were then added to the mixture at -78°C, and the mixture was stirred at 0°C for 1 h. Then 14-4 (787 mg, 6 mmol, 3 equivalents) and TEA (2.02 g, 20 mmol, 10 equivalents) were added to the mixture at -78 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (40 mL) and extracted with ethyl acetate (20 mL×3), and the combined organic layer was washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93%:7%) to obtain compound 14 (89 mg), which was separated by chiral HPLC to obtain compound 14a (36.3 mg) and compound 14b (34.3 mg).

[0393] Compound 14a:

[0394] LCMS: Rt = 1.665 min; m / z = 556 [M+1] + ;

[0395] 1 H NMR (400MHz, CDCl3) δ7.96 (d, J = 6.4Hz, 1H), 7.15-7.07 (m, 4H), 7.01 (m, 1H), 6.24 (s, 1H), 5.63 (s, 1H), 5.29-5.24 (m, 1H), 4.32 (m ,3H),4.14(m,3H),3.84(m,1H),3.48(m,3H),3.29(m,1H),3.02(m,1H),2.82(m,2H),1.75-1.61(m,3H),1.24(m,3H),0.85(m,3H).

[0396] Compound 14b:

[0397] LCMS: Rt = 2.332 min; m / z = 556 [M+1] + ;

[0398] 1 H NMR (400MHz, CDCl3) δ7.89 (d, J = 6.4Hz, 1H), 7.14-7.05 (m, 3H), 6.97 (m, 1H), 6.21(s,1H),5.53(s,1H),5.28(m,1H),4.39-4.23(m,4H),4.08(m,1H),4.03- 3.94(m,1H),3.74(m,1H),3.56-3.46(m,3H),3.46-3.34(m,2H),3.06(m,1H), 2.81(m,2H),1.74-1.67(m,3H),1.17(t,J=7.1Hz,3H),0.93(t,J=7.4Hz,3H).

[0399] Embodiment 11

[0400] Synthesis of compound 15

[0401]

[0402] To a solution of 15-1 (1000 mg, 4.044 mmol, 1.0 equiv) in anhydrous THF (20 mL) was added TEA (491.1 mg, 4.852 mmol, 1.2 equiv) at room temperature, and the mixture was stirred at room temperature for 30 min, and then POCl3 (744.1 mg, 4.852 mmol, 1.2 equiv) was added at -78°C. After 30 minutes, diisopropylamine (679.4 mg, 4.044 mmol, 1.0 equiv), ethyl 2-amino-2-methylpropanoate (636.2 mg, 4.044 mmol, 1.0 equiv) and TEA (4084.4 mg, 40.44 mmol, 10.0 equiv) in THF (20 mL) were added dropwise at 0°C and N2 to the above solution, and then the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (30 mL×3), and the combined organic layers were washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93:7) to give compound 15 (91.7 mg, 3.9% yield).

[0403] Compound 15:

[0404] LCMS: Rt = 2.4 min; m / z = 580 [M+1] + ;

[0405] 1 H NMR(400MHz, CDCl3)δ8.26(brs,1H),7.96-7.91(m,0.56H),7.90-7.84(m,0.42H) ,6.27(s,1H),5.99-5.72(m,1H),5.30(s,1H),4.36-4.24(m,1H),4.22-4.07(m,3H ),3.57-3.46(m,2H),3.39(d,J=9.1Hz,1H),3.11-3.04(m,1H),3.04-2.92(m,4H) ,1.53-1.44(m,8H),1.40-1.31(m,4H),1.24(t,J=7.1Hz,3H),0.89-0.81(m,12H).

[0406] Example 12

[0407] Synthesis of compound 16

[0408]

[0409] To a solution of 16-1 (1000 mg, 4.044 mmol, 1.0 equiv) in anhydrous THF (20 mL) was added TEA (491.1 mg, 4.852 mmol, 1.2 equiv) at room temperature, and the mixture was stirred at room temperature for 30 min, and then POCl3 (744.1 mg, 4.852 mmol, 1.2 equiv) was added at -78°C. After 30 minutes, diisopropylamine (679.4 mg, 4.044 mmol, 1.0 equiv), (S)-ethyl 2-aminobutyrate (1019 mg, 6.066 mmol, 1.5 equiv) and TEA (4084.4 mg, 40.44 mmol, 10.0 equiv) in THF (20 mL) were added dropwise at 0°C and N2 to the above solution, and then the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (30 mL×3), and the combined organic layers were washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=94:6) to give compound 16 (41.5 mg, 1.9% yield).

[0410] Compound 16:

[0411] LCMS: Rt = 2.43 min; m / z = 580 [M+1] + ;

[0412] 1 H NMR(400MHz, CDCl3)8.13(d,J=6.0Hz,0.57H),8.06(d,J=6.6Hz,0.26H),6.30-6. 23(m,1H),5.34-5.29(m,1H),4.41-4.28(m,1H),4.24-4.08(m,3H),3.88-3.68(m, 0.5H),3.59-3.48(m,1H),3.22-3.07(m,2H),3.06-2.86(m,4H),1.82-1.65(m,2H) ,1.56-1.44(m,2H),1.41-1.32(m,4H),1.25(t,J=7.1Hz,3H),0.91-0.84(m,17H).

[0413] Example 13

[0414] Synthesis of compound 17

[0415]

[0416] To a solution of 17-1 (500 mg, 2.02 mmol, 1.0 equiv) in anhydrous THF (15 mL) was added TEA (265 mg, 2.63 mmol, 1.3 equiv) at 0°C and N2. After stirring for 1 hour, POCl3 (403 mg, 2.63 mmol, 1.3 equiv) was added to the reaction mixture at -78°C and N2, and the solution was then stirred at -78°C for 1 hour. Then, 17-3 (318 mg, 2.02 mmol, 1.0 equiv) and TEA (1.43 g, 14.15 mmol, 7.0 equiv) were added to the mixture at 0°C, and the mixture was stirred at 0°C for 2 hours. Then 17-4 (845 mg, 5.06 mmol, 2.5 equivalents) and TEA (1.43 g, 14.15 mmol, 7.0 equivalents) were added to the mixture at 0 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (25 mL × 3), and the combined organic layers were washed with brine (15 mL × 3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by preparative HPLC to give compound 17 (230 mg, 20% yield).

[0417] Compound 17:

[0418] LCMS: Rt = 2.100 min; m / z = 580 [M+1] + ;

[0419] 1 H NMR (400MHz, CDCl3) δ9.53(s,2H),8.17(m,1H),7.45(s,1H),6.22(m,1H),5.29(m,1H),4.95(m,1H),4.31(m,1H),4.16(m,1H ),3.79(m,1H),3.50(m,1H),3.13(m,2H),2.95(m,4H),1.47(m,2H),1.32(m,6H),1.18(m,7H),0.83(dd,J=6.4,2.5Hz,12H).

[0420] HPLC: Rt = 7.299 min; 100% purity (UV 220), 100% purity (UV 254).

[0421] Embodiment 14

[0422] Synthesis of compound 18

[0423]

[0424] To a solution of 4-amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one (1 g, 4 mmol, 1.0 eq) in THF (20 mL) was added TEA (531 mg, 5.2 mmol, 1.3 eq) at 0°C, and the mixture was stirred under N2 and 0°C for 0.5 h. POCl3 (795.6 mg, 5.2 mmol, 1.3 eq) was then added to the reaction mixture at -78°C, and the mixture was stirred at 0°C for 1 h. 18-3 (788.9 mg, 4 mmol, 1.0 eq) and TEA (1.212 g, 12 mmol, 3 eq) were then added to the mixture at -78°C, and the mixture was stirred at 0°C for 1 h. Then 18-4 (1.574 g, 12 mmol, 3.0 equivalents) and TEA (2.02 g, 20 mmol, 10 equivalents) were added to the mixture at -78 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (60 mL) and extracted with ethyl acetate (30 mL×3), and the combined organic layer was washed with brine (30 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93%:7%) to give compound 18 (492.3 mg).

[0425] Compound 18:

[0426] LCMS: Rt = 1.891 min; m / z = 620 [M+1] + ;

[0427] 1 H NMR (400MHz, CDCl3) δ7.98(m,1H),7.11(m,1H),6.86-6.70(m,2H),6.58(s,1H),6.31(s,1H),5.34(s,2H),4.42-4.25(m,2H),4.18(m,2H),3. 76(s,2H),3.66(m,1H),3.54(m,2H),3.36(m,1H),3.11(m,1H),2.90(m ,1H),2.79(s,2H),1.77(m,2H),1.56(m,4H),1.53(m,4H),1.27(m,3H).

[0428] Embodiment 15

[0429] Synthesis of compound 19

[0430]

[0431] To a solution of 19-1 (300 mg, 1.21 mmol, 1.0 equiv) in anhydrous THF (5 mL) was added TEA (490 mg, 4.85 mmol, 1.2 equiv) at room temperature and N2. After stirring for 30 minutes, POCl3 (223 mg, 1.45 mmol, 1.2 equiv) was added to the reaction mixture at -78°C and N2, and the solution was then stirred at -78°C for 0.5 hours. To the above solution was added dropwise a mixture of 19-3 (283 mg, 1.45 mmol, 1.2 equiv), 19-4 (305 mg, 1.82 mmol, 1.2 equiv) and TEA (1.23 g, 12.1 mmol, 10 equiv) in THF (5 mL) at -78°C and N2, and the mixture was then stirred at room temperature overnight. The reaction mixture was quenched with H2O (10 mL) and extracted with DCM (30 mL×3), and the combined organic layers were washed with brine (30 mL×2), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93:7) to give compound 19 (120 mg, 16% yield).

[0432] Compound 19:

[0433] LCMS: Rt = 1.969 min; m / z = 620 [M+1] + ;

[0434] 1 H NMR (400MHz, CDCl3) δ7.95 (t, J = 6.0 Hz, 1H), 7.82 (s, 1H), 7.10 (s, 1H), 6.86-6.70 (m, 2H), 6.29 (d, J = 5. 0Hz,1H),5.67(s,1H),5.33(s,1H),4.33(m,J=22.2,6.8Hz,2H),4.24-4.07(m,2H),3.85(d,J=15.3Hz, 0.5H),3.74(s,3H),3.51(t,J=11.5Hz,1H),3.30(t,J=10.2Hz,0.5H),3.10(t,J=12.7Hz,1H),2.96-2. 75(m,3H),1.74(dd,J=17.0,10.1Hz,4H),1.59(d,J=12.9Hz,2H),1.28-1.24(m,3H),0.96-0.88(m,3H).

[0435] Example 16

[0436] Synthesis of compound 20

[0437]

[0438] To a solution of 20-1 (1 g, 4.0 mmol, 1.0 eq) in anhydrous THF (15 mL) was added TEA (490 mg, 4.85 mmol, 1.2 eq) at room temperature and N2. After stirring for 30 minutes, POCl3 (744 mg, 4.85 mmol, 1.2 eq) was added to the reaction mixture at -78°C and N2, and the solution was then stirred at -78°C for 0.5 hours. To the above solution was added dropwise a mixture of 20-3 (634 mg, 4.04 mmol, 1 eq), 20-4 (714 mg, 6.06 mmol, 1.5 eq) and TEA (4.08 g, 40.4 mmol, 10 eq) in THF (10 mL) at 0°C and N2, and the mixture was then stirred at room temperature for 30 minutes. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (50 mL×3), and the combined organic layers were washed with brine (50 mL×2), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93:7) to give compound 20 (720 mg, 32% yield).

[0439] Compound 20:

[0440] LCMS: Rt = 2.350 min; m / z = 566 [M+1] + ;

[0441] 1 H NMR (400MHz, CDCl3) δ8.05(d,J=18.8Hz,1H),5.32(s,1H),4.35(s,1H),4.27-4.10(m,3H),3.98-3.77(m,1H),3.51(t,J=15.6Hz,1 H),3.15(t,J=21.1Hz,2H),3.00(d,J=6.8Hz,4H),1.54-1.46(m,2H),1.40-1.35(m,6H),1.27-1.22(m,6H),0.88(d,J=6.4Hz,12H).

[0442] Embodiment 17

[0443] Synthesis of compound 21

[0444]

[0445] To a solution of 21-1 (500 mg, 2.02 mmol, 1.0 equiv) in anhydrous THF (15 mL) was added TEA (265 mg, 2.63 mmol, 1.3 equiv) at 0°C and N2. After stirring for 1 hour, POCl3 (403 mg, 2.63 mmol, 1.3 equiv) was added to the reaction mixture at -78°C and N2, and the solution was then stirred at -78°C for 1 hour. Then, 21-3 (318 mg, 2.02 mmol, 1.0 equiv) and TEA (1.43 g, 14.15 mmol, 7.0 equiv) were added to the mixture at 0°C, and the mixture was stirred at 0°C for 2 hours. Then 21-4 (915 mg, 5.06 mmol, 2.5 equivalents) and TEA (1.43 g, 14.15 mmol, 7.0 equivalents) were added to the mixture at 0 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (25 mL×3), and the combined organic layers were washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by preparative HPLC to give compound 21 (170 mg, 14% yield).

[0446] Compound 21

[0447] LCMS: Rt = 2.233 min; m / z = 594 [M+1] + ;

[0448] 1 H NMR(400MHz, CDCl3)δ9.53(s,2H),8.17(m,1H),7.45(s,1H),6.22(m,1H),5.29(m,1H),4.95(m,1H),4.31(m,1H),4.16(m,1H ),3.79(m,1H),3.50(m,1H),3.13(m,2H),2.95(m,4H),1.47(m,2H),1.32(m,6H),1.18(m,7H),0.83(dd,J=6.4,2.5Hz,12H).

[0449] HPLC: Rt = 7.548 min; 100% purity (UV 220), 100% purity (UV 254).

[0450] Embodiment 18

[0451] Synthesis of compound 22

[0452]

[0453] To a solution of 22-1 (600 mg, 2.43 mmol, 1.0 equiv) in anhydrous THF (10 mL) was added TEA (318.7 mg, 3.15 mmol, 1.3 equiv) at room temperature, the mixture was stirred at room temperature for 30 min, and then POCl3 (482.9 mg, 3.15 mmol, 1.3 equiv) was added at -78 ° C. After 30 minutes, diisopropylamine (675 mg, 1.5 equiv) was added dropwise to the above solution at 0 ° C and N2. , 3.645mmol, 1.5 equivalents) and TEA (1721mg, 17.01mmol, 7.0 equivalents) in THF (10mL) solution, then at 0°C and N2, (S)-isopropyl 2-aminopropanoate (1633mg, 9.72mmol, 4.0 equivalents) and TEA (1721mg, 17.01mmol, 7.0 equivalents) in THF (10mL) solution were added dropwise, and the mixture was subsequently stirred at 40°C for 48 hours. The reaction mixture was quenched with H2O (30mL) and extracted with DCM (30mL×3), and the combined organic layers were washed with brine (50mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93:7) to give compound 22 (101.7mg, 6.9% yield).

[0454] Compound 22:

[0455] LCMS: Rt = 2.43 min; m / z = 608 [M+1] + ;

[0456] 1 H NMR(400MHz, CDCl3)δ8.03-7.98(m,0.5H),7.91-7.86(m,0.5H),6.31-6.20(m,1H),5.60-5 .44(m,0.5H),5.34-5.25(m,1H),5.05-4.92(m,1H),4.45-4.36(m,0.3H),4.30-4.12(m,1H ),3.96-3.78(m,1H),3.58-3.46(m,1H),3.22(t,J=9.7Hz,0.3H),3.13-3.01(m,1H),2.94- 2.80(m,4H),1.54-1.42(m,2H),1.41-1.26(m,8H),1.24-1.15(m,9H),0.88-0.77(m,12H).

[0457] Embodiment 19

[0458] Synthesis of compound 23

[0459]

[0460] To a solution of 23-1 (600 mg, 2.43 mmol, 1.0 equiv) in anhydrous THF (10 mL) at room temperature was added TEA (318.7 mg, 3.15 mmol, 1.3 equiv). The mixture was stirred at room temperature for 30 min, and then POCl3 (482.9 mg, 3.15 mmol, 1.3 equiv) was added at -78 °C. After 30 min, bis(2-ethylbutyl)amine (67 5mg, 3.645mmol, 1.5 eq.) and TEA (1721mg, 17.01mmol, 7.0 eq.) in THF (10mL) solution, then at 0°C and N2, (S)-ethyl 2-aminobutyrate (1633mg, 9.72mmol, 4.0 eq.) and TEA (1721mg, 17.01mmol, 7.0 eq.) in THF (10mL) solution were added dropwise, and the mixture was subsequently stirred at 40°C for 48 hours. The reaction mixture was quenched with H2O (30mL) and extracted with DCM (30mL×3), and the combined organic layers were washed with brine (50mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=93:7) to give compound 23 (179.5mg, 12.1% yield).

[0461] Compound 23:

[0462] LCMS: Rt = 2.607 min; m / z = 608 [M+1] + ;

[0463] 1 H NMR(400MHz, CDCl3)δ8.00(m,0.5H),7.85(m,0.5H),7.78(s,0.5H),6.26(s,1H), 5.61(s,1H),5.30(d,J=4.7Hz,1H),4.39(m,0.5H),4.28-4.22(m,1H),4.20-4.08 (m,3H),3.85(m,1H),3.57-3.46(m,1H),3.15(t,J=9.7Hz,0H),3.05(m,2H),2.95 -2.81(m,4H),1.82-1.65(m,2H),1.47(s,2H),1.28(m,12H),0.91-0.80(m,16H).

[0464] Embodiment 20

[0465] Synthesis of compound 24

[0466]

[0467] To a solution of 24-1 (500 mg, 2.02 mmol, 1.0 equiv) in anhydrous THF (15 mL) was added TEA (265 mg, 2.63 mmol, 1.3 equiv) at 0°C and N2. After stirring for 1 hour, POCl3 (403 mg, 2.63 mmol, 1.3 equiv) was added to the reaction mixture at -78°C and N2, and the solution was then stirred at -78°C for 1 hour. Then, 24-3 (485 mg, 2.63 mmol, 1.0 equiv) and TEA (1.43 g, 14.15 mmol, 7.0 equiv) were added to the mixture at 0°C, and the mixture was stirred at 0°C for 2 hours. Then 24-4 (1.46 g, 8.09 mmol, 4.0 equivalents) and TEA (1.43 g, 14.15 mmol, 7.0 equivalents) were added to the mixture at 0 ° C, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was quenched with H2O (30 mL) and extracted with DCM (25 mL × 3), and the combined organic layers were washed with brine (15 mL × 3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by preparative HPLC to give compound 24 (285 mg, 20% yield).

[0468] Compound 24:

[0469] LCMS: Rt = 2.500 min; m / z = 622 [M+1] + ;

[0470] 1 H NMR (400MHz, CDCl3) δ7.96(m,1H),6.96(s,1H),6.27(s,1H),5.44(s,1H),5.31(s,1H),4.34(m,1H),4.12(m,2H),3.96(m,1 H),3.53(m,1H),3.12(m,1H),2.89(m,4H),1.60(m,2H),1.49(m,2H),1.35(m,10H),1.24(m,5H),0.91m,3H),0.85(m,12H).

[0471] HPLC: Rt = 7.304 min; 98% purity (UV 220), 97% purity (UV 254).

[0472] Embodiment 21

[0473] Synthesis of compound 25

[0474]

[0475] To a solution of 25-1 (200 mg, 0.81 mmol, 1.0 equiv) in anhydrous THF (5 mL) at room temperature was added TEA (106.5 mg, 1.053 mmol, 1.3 equiv). The mixture was stirred at room temperature for 30 min, and then POCl3 (161.5 mg, 1.053 mmol, 1.3 equiv) was added at -78 °C. After 30 min, bis(3,3-dimethylbutyl)amine ( 225.3mg, 1.215mmol, 1.5 equivalents) and TEA (0.79mL, 5.67mmol, 7.0 equivalents) in THF (5mL) solution, then at 0 ° C and N2, (S)-isopropyl 2-aminopropanoate (544.32mg, 3.24mmol, 4.0 equivalents) and TEA (0.79mL, 5.67mmol, 7.0 equivalents) in THF (5mL) solution were added dropwise, and the mixture was stirred at 40 ° C for 48 hours. The reaction mixture was quenched with H2O (30mL) and extracted with DCM (30mL×3), and the combined organic layers were washed with brine (50mL×3), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel flash column chromatography (DCM / MeOH=96:4) to give compound 25 (111.5mg, 22.6% yield).

[0476] Compound 25:

[0477] LCMS: Rt = 2.28 min; m / z = 608 [M+1] + ;

[0478] 1 H NMR (400MHz, CDCl3) δ7.96 (dd, J=17.3, 6.2Hz, 1H), 7.63 (s, 1H), 6.27 (s, 1H), 5.56 (s, 1H),5.35-5.27(m,1H),5.06-4.92(m,1H),4.40-4.28(m,1H),4.27-4.14(m,1H),3.94- 3.74(m,1H),3.53(dd,J=12.1,5.0Hz,1H),3.22(dt,J=32.0,9.8Hz,1H),3.10(d,J=12. 0Hz,1H),3.04-2.91(m,4H),1.43-1.33(m,8H),1.24-1.19(m,6H),0.89-0.84(m,18H).

[0479] Embodiment 22

[0480] Antiviral experiments

[0481] In vitro antiviral activity against HBV

[0482] In vitro anti-HBV activity and cytotoxicity were evaluated using HepG2.2.15 cells as described below.

[0483] Antiviral activity assay: HepG2.2.15 cells were cultured at 1×10 5 Cells were seeded at a density of 10 cells / well into 96-well plates and maintained at 37°C / 5% CO2. After 24 hours of incubation, different concentrations of test compounds and positive controls (3TC and FTC) as well as control samples without inhibitors (DMSO only) were added. The test compounds were evaluated by an 8-point serial dilution method, with 3-fold dilutions at each point. After 72 hours of incubation, the original culture medium was replaced with fresh culture medium containing the same test compounds / positive controls at the same concentrations and cultured for another 3 days. After 6 days, the supernatant of the cell culture medium was collected and the HBV DNA content was determined by quantitative polymerase chain reaction (qPCR) assay. The inhibition % was calculated by the following equation: Inhibition (%) = 100-(DNA replication of test sample) / (DNA replication of DMSO) × 100. EC 50 The inhibition curves were determined and the results are shown in Table 2.

[0484] Cytotoxicity assay: Cytotoxicity was evaluated using a luminescent cell viability assay. HepG2.2.15 cells were inoculated using the same method as the antiviral activity assay and incubated in the presence of test compounds / positive controls. After 6 days of incubation, Cell-Titer Glo (Promega) was added to each well and luminescence was recorded for cell viability assay. Cell viability % was calculated by the following equation:

[0485] Cell viability (%) = (luminescence of test sample - average luminescence of culture medium) / (average luminescence of control sample - average luminescence of culture medium) × 100. 50 The results were determined from the activity curve and are shown in Table 2.

[0486] Table 2

[0487]

[0488]

[0489] EC 50 :A:<100nM

[0490] In vitro antiviral activity against HIV

[0491] In vitro anti-HIV activity and cytotoxicity were evaluated using MT-4 cells as described below.

[0492] Antiviral activity assay: MT4 cells were incubated with HIV-1IIIB at 37°C / 5% CO2 for 1 hour. 4 The cells were seeded into 96-well plates at a density of 10 cells / well. Test compounds and positive controls (FTC) were added in an 8-point serial dilution format (each point was diluted 3 times), as well as virus control samples without inhibitors (DMSO only) and uninfected cell control samples. After incubation for 5 to 6 days at 37°C / 5% CO2, the virus-induced cytopathic effect was determined by luminescent cell viability assay using Cell-TiterGlo (Promega). Inhibition % was calculated by the following equation: Inhibition (%) = (luminescence of test sample - average luminescence of virus control) / (average luminescence of uninfected cell control - average luminescence of virus control) × 100. EC 50 The inhibition curves were determined and the results are shown in Table 3.

[0493] Cytotoxicity assay: Cytotoxicity was evaluated using a luminescent cell viability assay. Uninfected MT-4 cells were inoculated using the same method as the antiviral activity assay and incubated in the presence of test compounds / positive controls. After 5 to 6 days of incubation, Cell-Titer Glo (Promega) was added to each well and luminescence was recorded for cell viability assay. Cell viability % was calculated by the following equation:

[0494] Cell viability (%) = (luminescence of test sample - average luminescence of culture medium) / (average luminescence of uninfected cell control - average luminescence of culture medium). CC 50 The results were determined from the activity curve and are shown in Table 3.

[0495] Table 3

[0496]

[0497] EC 50 :A:<100nM

[0498] As can be seen from Table 2 and Table 3, the compounds of the present disclosure have strong inhibitory effects on HBV and HIV viruses and low cytotoxicity, which is comparable to the positive control 3TC or FTC.

[0499] Embodiment 23

[0500] Evaluation of Prodrug Conversion in Human Peripheral Blood Mononuclear Cells (PBMCs)

[0501] Cryopreserved human PBMCs were used to evaluate the conversion of the prodrug to the active triphosphate form. PBMCs were cultured at 2*10 6 / mL of cell density in culture medium and incubate at 37°C / 5% CO2 for 1 hour. After cell recovery, 5mL of cell suspension was transferred to a 15mL test tube and mixed with 5mL of test compound (prodrug), parent drug (FTC or 3TC) or reference compound 1 (isopropyl ((((2R,5S)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-1,3-oxathiolan-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate) at 5μM in culture medium. After incubation at 37°C / 5% CO2 for another 3 hours, the sample was centrifuged at 300g for 10 minutes and the supernatant was discarded. The cell pellet was washed twice with 10mL of ice-cold PBS and lysed with 700μL of 70% methanol. The lysate was placed at -20°C overnight and centrifuged at 10000rpm for 10 minutes at 4°C. Finally, 650 μ L supernatants are transferred to clean 96 orifice plates and evaporated to dryness with nitrogen. The dry residue is then dissolved with 200 μ L initial LC mobile phases and loaded into the LC-MS / MS instrument. The response of the monophosphate, diphosphate or triphosphate metabolites of the parent drug (FTC or 3TC) and the parent drug is measured for each sample. In order to assess conversion efficiency, the response ratio of every kind of analyte (monophosphate, diphosphate or triphosphate metabolites) measured from the test compound is calculated relative to the parent drug, and is reported in Table 4.

[0502] Table 4: Intracellular concentrations relative to FTC after 180 min incubation with PBMC

[0503]

[0504] It can be seen that compared to the FTC parent drug, the compounds of the present disclosure are converted into FTC phosphates (monophosphate, diphosphate and triphosphate) in PBMCs, and the concentrations of these FTC phosphates are higher than the corresponding concentrations of FTC phosphates produced by metabolism of the FTC parent drug and reference compound 1.

[0505] Evaluation of prodrug conversion in Hep G2 cells

[0506] Hep G2 cells were also used to evaluate the conversion of the prodrug to the active triphosphate form. Hep G2 cells were digested with 0.25% trypsin-0.53 mM EDTA and plated at 2 × 10 6The cells were suspended at a density of 1 mL / mL. In order to inoculate cells, 1.5 mL of culture medium and 1 mL of cell suspension were added to each well of a 6-well plate. Gently shaken, the plate was placed in an incubator at 37°C / 5% CO2 overnight to allow cell attachment. After cell attachment, the original culture medium was replaced with a fresh culture medium containing 5 μM test compound (prodrug), parent drug (FTC or 3TC) or reference compound 1, and incubated at 37°C / 5% CO2. At a specific time point (1 hour, 4 hours, 7 hours, 24 hours), the culture medium was removed, and the cells were washed twice with 3 mL of ice-cold PBS. After washing, the cells were dissociated at 20°C for 5 minutes with 100 μL of 0.25% trypsin-0.53 mM EDTA, and lysed with 500 μL of ice-cold 70% methanol. The lysate was placed at -20°C for lysis, and centrifuged at 10000 rpm for 10 minutes at 4°C. Finally, 600 μ L supernatant was transferred to a clean 96-well plate and evaporated to dryness with nitrogen. The dried residue was then dissolved with 200 μ L initial LC mobile phases and loaded into the LC-MS / MS instrument. The response of the triphosphate metabolite was determined for each sample. In order to assess conversion efficiency, the triphosphate metabolite measured from the test compound at each time point was calculated relative to the response ratio of the parent drug, and reported in Table 5.

[0507] Table 5. Intracellular triphosphate concentrations relative to FTC after incubation with Hep G2 cells at different time points

[0508]

[0509]

[0510] It can be seen that compared with the FTC parent drug, the compounds of the present disclosure are converted into FTC phosphates (monophosphate, diphosphate and triphosphate) in Hep G2 cells, and the concentrations of these FTC phosphates are higher than the corresponding concentrations of FTC phosphates produced by the metabolism of the FTC parent drug and reference compound 1.

[0511] Although the invention has been described in conjunction with specific embodiments thereof, it will be understood that the invention is capable of further modifications, and this application is intended to cover any changes, uses, or adaptations of the invention which generally follow the principles of the invention and include such departures from the present disclosure as come within the known or customary practice in the art to which the invention pertains and which apply to the basic characteristics hereinbefore described, and which fall within the scope of the appended claims.

Claims

1. Use of a compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing or treating viral infection, wherein the compound is selected from:

2. The use according to claim 1, wherein The viral infection is HBV infection or HIV infection.